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ABSTRACT
The level of torsion in double-stranded DNA regulates base-pair stability and
DNA conformation. It is important in initiation and regulation of specific DNA metabolic
processes as well as chromatin assembly. High mobility group proteins (HMGB) are
architectural proteins whose HMG DNA binding domains confer significant preference
for distorted DNA, such as supercoiled DNA and 4-way junctions. HMGB proteins play
a role in transiently regulating or conserving DNA torsion. Topoisomerases regulate
DNA supercoiling, which has been argued to provide a coherent explanation for the main
modes of transcriptional control - stringent control, growth-rate control and growth-phase
control during normal cell growth.
In this study, we have shown that HMO1, a Saccharomyces cerevisiae HMGB
protein which is required for normal growth, plasmid maintenance and regulating the
susceptibility of yeast chromatin to nuclease, binds linear duplex DNA but has little
preference for DNA with altered conformations. The divergent box A binds DNA and
contributes structure-specific binding. Unlike most HMGB proteins, HMO1 does not
supercoil relaxed DNA in the presence of topoisomerase. Casein Kinase II
phosphorylates HMO1, altering its DNA binding properties. We have also shown that
deletion of the highly basic C-terminal tail of HMO1 localizes this otherwise nuclear and
cytoplasmic protein only to the cytoplasm. As the C-terminally truncated HMO1 has
been reported to rescue the hmo1 knockout phenotype, we conclude that the main
function of HMO1 lies in the cytoplasm, and not in the nucleus.
Vaccinia topoisomerase I relaxes supercoiled DNA. We have shown that it
interacts with enrofloxacin, a fluoroquinolone antibiotic which otherwise targets DNA
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gyrase and topoisomerase IV. Enrofloxacin inhibits DNA relaxation by Vaccinia
topoisomerase I. When presented with relaxed DNA, the enzyme executes the reverse
reaction, supercoiling the DNA. Enrofloxacin does not interfere with the catalytic
cleavage site of Vaccinia topoisomerase I or its ability to bind DNA. The mechanistic
implication of these observations is that protein-DNA contacts downstream of the
cleavage site must contribute to DNA supercoiling, contrary to the free rotation
mechanism proposed for DNA relaxation.
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CHAPTER 1
INTRODUCTION
DNA topology is critical in cellular processes such as replication, transcription,
recombination, chromosome condensation and much more. DNA topology must therefore
be fine-tuned to allow these critical processes to optimally proceed as deemed. High
Mobility Group proteins (HMG) are DNA architectural proteins that have been shown to
participate in these processes and have been shown to introduce supercoils into closed
circular DNA in the presence of topoisomerase. Topoisomerases are proteins that
remove/regulate DNA supercoiling, playing a critical role in the above mentioned cellular
processes. In fact, drugs that interfere with the function of topoisomerases are in wide use
both clinically and in research. We are describing HMO1, a Saccharomyces cerevisiae
HMG protein that differs in its activity from previously characterized homologs in that it
does not supercoil DNA. We also show unusual properties of Vaccinia topoisomerase I;
this enzyme interacts with a fluoroquinolone drug enrofloxacin, which causes it to
execute the reverse reaction, supercoiling DNA when presented with closed circular
DNA, as opposed to relaxing supercoiled DNA.
High-Mobility-Group (HMG) Proteins
HMG are a family of ubiquitous proteins that constitute a significant fraction of
non-histone nuclear proteins. They were first extracted from nuclei with 0.35 M NaCl by
the British scientist H. M. Goodwin, and the name indicates that they are small proteins
that run fast in SDS-polyacrylamide gels [1]. They consist of three subfamilies: HMGA,
HMGB, and HMGN. HMG proteins are united by a common theme in that they alter the
local conformation of DNA or nucleosomes, thus increasing their accessibility and
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plasticity, and facilitating and enhancing various DNA-dependent activities such as
transcription, replication, recombination and DNA repair [2-5]. The three subfamilies
have a characteristic motif, such as the HMG-box in HMGBs, the AT-hook in HMGAs,
and the nucleosomal binding domain in HMGNs. My dissertation will focus on the
HMGB group of proteins to which HMO1, the protein of my dissertation research,
belongs.
Classification of HMGB Proteins
HMGB proteins contain one or more homologous repeats of the ~80-amino acid
sequence HMG box and are classified into two families based on their abundance,
function and DNA specificity of this conserved region [2, 6-7]. The moderately
sequence-specific family are transcription factors that usually contain a single HMG box
and recognize dsDNA. They are typified by transcription factors such as sex-determining
factor SRY and lymphoid enhancer factor LEF-1 [8, 9]. The non-sequence specific
family binds DNA without sequence preference but instead structural preference. They
are represented by the so-called architectural factors HMGB1/2, ubiquitous proteins in
vertebrates, and the Saccharomyces cerevisiae non-histone chromosomal protein 6A and
6B (NHP6A/B) [10]. HMGB1/2 have two HMG boxes (A and B) and a long acidic tail
containing aspartic or glutamic acid residues, linked to the HMG boxes by a region of
basic residues. Most HMG-box proteins in organisms other than vertebrates have only a
single HMG box which sometimes is accompanied by an acidic tail (e.g., HMG-D,
HMG-Z [11,12]), but not always (e.g., NHP6A/B, [13]). NHP6A/B contains a highly
basic amino acid region in front of the HMG box that has been shown to be important for
elevated DNA binding affinity [14].
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Structure of HMGB Proteins
Several structures of HMG boxes from both the non-sequence specific subfamily
and the sequence specific subfamily of proteins have been determined in the presence
and/or absence of DNA. Non-sequence specific HMG boxes for which structures have
been determined in the absence of DNA include HMGB1 box A [15], HMGB1 box B
[16, 17], HMG-D [18] and NHP6A [19]. Masse et al., later determined the structure of
NHP6A in the presence of DNA [20]. The structure of SOX4, a sequence specific HMG
box protein was determined in the absence of DNA [21], while the structures of two
sequence specific HMG proteins, SRY and LEF-1 were determined in the presence of
their cognate DNA recognition sequence [22, 23].
The structures of both sequence specific and non-sequence specific homologs
have been determined to have the same general global fold, characterized by a 3dimensional, L-shaped structure with three α-helices (reviewed in [4, 24-25]). The long
arm consists of the amino-terminal extended peptide and helix III, while the shorter arm
comprises two central helices I and II. A hydrophobic core of conserved aromatic
residues from the three α-helices is maintained at the apex of the L-shaped structure. This
region has the most highly conserved amino acid residues in the HMG boxes. Outside the
hydrophobic core, the conservation scores decline, getting lower gradually with
procession toward the end of either arm of the protein. This trend probably reflects the
relative importance of the various regions of the protein for adopting the HMGB fold.
Binding Targets of HMG Boxes
The structure of the sequence specific proteins show the DNA to be greatly
distorted in the region of protein contact, with SRY introducing a bend of 80° [23] while
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LEF-1 introduces a 120° bend [9]. The HMG box binds to the minor groove of B-form
DNA with its concave face and causes bending by partial insertion of hydrophobic
residues close to the amino-terminus of helix I into the minor groove of the DNA. As a
consequence, the DNA is severely underwound and widened, thus increasing the proteinDNA interface. The DNA is kinked towards the opposing major groove which is thereby
highly compressed. Hydrophobic interactions as well as hydrogen bonds between the
proteins and the DNA sequence mediate the specificity of this class of HMGB protein
[20].
Determinants of Sequence-Specific Versus Non-Sequence Specific HMGB Proteins
Detailed structures of the non-sequence specific proteins have reiterated the main
features of interaction but also reveal interesting and important differences. Extensive
phylogenetic analysis by Masse et al., revealed determinants of sequence-specific versus
non-sequence specific HMGB proteins [20]. Using NHP6A as a common reference
frame, these authors noted that the residue in position 57 shows the most statistically
significant correlation to DNA recognition type (Figure 1.1). For non-sequence specific
HMGB proteins, this position is almost always negatively charged and most likely to be
involved in stabilizing the fold of helix 2, as it is often surrounded by positively charged
residues. Conversely, a variety of residues are present in this position in sequence
specific HMGB proteins. Other negatively charged residues in helix 1 and helix 3 show
correlation with non-sequence specificity, but not as significant as the residue in position
57. These authors speculated that these negative charges may be involved in restricting
the path of the DNA on the protein through electrostatic repulsion, a function that
sequence specific DNA-binding proteins can achieve by forming sequence specific
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Helix II

Helix I
29

48

57

NHP6A
HMGB1
HMGD

PKRALSAYMFFANENRDIVRSENPD ITFGQVGKKLGEKWKALTPEEKQPYEA
PRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFED
PKRPLSAYMLWLNSARESIKRENPG IKVTEVAKRGGELWRAM KDKSEWEA

HMO1

PKKPLTVFFAYSAYVRQELREDLPP

LSSTEITQEISKKWKELSDNEKEKWKQ

LEF-1
SRY
UBF

IKKPLNAFMLYMKEMRANVVAECTL
VKRPMNAFIVWSRDQRRKMALENPR
PKKPLTPYFRFFMEKRKYAKLH PE

KESAAINQILGRRWHALSREEQAKYYE
MRNSEISKQLGYQWKMLTEAEKWPFFQ
MSNLDLTKILSKKYKELPEKKKMKYIQ

Figure 1.1 Alignment of HMG-box helices I and II. For non-sequence specific proteins,
S. cerevisiae NHP6A along with box A of rat HMGB1, Drosophila melanogaster HMGD
and box B of S. cerevisiae HMO1. Sequence specific proteins are mouse LEF-1, human
SRY, and Xenopus laevis UBF box A. Residues corresponding to positions 29, 48 and 57
of NHP6A helices I and II, respectively, are in bold.
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hydrogen bonds with DNA. Another important position that correlates to specificity of
the HMGB proteins is 48 which is almost always a bulky hydrophobic residue in nonsequence specific proteins. In the structure of NHP6A and HMG-D, it has been shown
that it contributes to DNA bending by re-directing the trajectory of the DNA as it exits
the protein [20, 22]. This exit wedge has also been shown to be the critical determinant
for selective binding by both HMGB1 Box A and NHP6A to pre-bent DNA resulting
from cisplatin modification or a bulge. In sequence specific proteins, this position usually
has a hydrophilic, often charged residue which makes specific hydrogen bonds to the
cognate DNA. These specific hydrogen bonds within the minor groove are believed to
direct the sequence specific HMGB proteins to specific DNA targets. The means by
which non-sequence specific HMGB proteins pick their B-DNA target seems different
from sequence specific DNA binding proteins. Looking at NHP6A and HMG-D
structures, it appears that Met29 is of primary importance for selecting a deformable
base-pair step in B-DNA. Clear and striking evidence of the difference in modes of
recognition between sequence specific and non- sequence specific homologs is seen
when the structures of NHP6A-DNA and SRY-DNA is compared (Figure 1.2). The two
proteins bind to the related DNA sequence in opposite orientations and 1 bp step shifted
[20, 23].
The Role of HMG Box Basic Extensions
Basic extensions found either C- or N-terminal to the HMG box are known to
increase the bending capacity and DNA-binding affinity of the HMG box. For example,
the 16 basic amino acids found in the N-terminus of the NHP6A HMG box is required for
stable complex formation on both linear DNA and DNA minicircles. At high
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NHP6A

SRY

Figure 1.2 Cocrystal structure of NHP6A and SRY with DNA. Comparison of solution
structures of NHP6A-DNAsry and SRY-DNA (Protein data bank (PDB) accession
numbers 1LWM and 1HRZ respectively) [20, 23]. DNA is shown in backbone model to
clearly demonstrate that the two proteins (shown in ribbon form) bind related DNA
sequence in opposite orientations.
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concentrations, mutants lacking the N-terminus are able to promote minicircle formation
and Hin invertasome assembly, but they are unable to form stable complexes with DNA,
co-activate transcription, and complement the growth defect of ∆nhp6a/b mutants [14].
Basic C-terminal extensions stabilize binding of HMG-D and LEF-1 by binding in the
major groove opposite the distorted minor grove [22, 26].
HMGB1/2 Acidic C Terminal Tail
The HMGB1/2 acidic tail has been shown to lower the affinity of the HMG boxes
for most DNA substrates, such as linear DNA, supercoiled DNA and four-way junctions.
Interestingly, the tail is essential for structure-selective DNA-binding of the HMG boxes
to DNA minicircles, and it has little effect on the affinity for DNA minicircles compared
to other DNA substrates in vitro [27]. However, it was not established whether this is a
consequence of interaction of the tail with the HMG box(es) or the basic extension region
or simply charge repulsion. Thomsen et al. [28] showed that the interactions of the basic
N-terminal and acidic C-terminal domains of the maize HMGB1 may contribute to the
regulation of the DNA interactions of the protein. A similar phenomenon was also
observed for the Arabidopsis HMGB1 and HMGB4 [28]. This led the authors to argue
that the interaction of the variable terminal domains of the different

plant HMGB

proteins could serve as a molecular mechanism involved in the fine tuning of the
functional properties of these architectural proteins depending on the structural
requirements of specific nucleoprotein complexes.
Shirakawa et al. showed that the acidic tail may be involved in nuclear retention
of HMGB2 [29]. In cells overexpressing HMGB1, the protein was shown to bind to a
minichromosome derived from the transfected reporter plasmid, substituting for linker
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histone H1, and to stimulate transcription from the reporter plasmid accompanied by
decondensation of the minichromosome structure [30]. In addition, the acidic tail is
required for stimulation of transcription [31] and it has recently also been demonstrated
to stimulate nucleosome sliding by the chromatin remodeling factor ACF/CHRAC [32].
This study also showed that the HMGB1 acidic tail is a dominant factor involved in its
binding to the nucleosome and is required for binding to nucleosome linker DNA.
The Diverse Roles of HMGB1 in vivo
HMGB1 protein has been shown to interact with a diverse set of proteins. It plays
an important role in transcription by interacting with several transcription factors, viral
replication proteins, the RAG1 recombinase, and steroid receptors [33]. Hmgb1 knockout
mice die soon after birth with defects in the function of steroid receptors revealing that
the gene is essential [34]. HMGB1 is the most mobile nuclear protein [35]. Manfredi and
Bianchi (review in [36]) referred to HMGB1 as a chromatin chaperone that uses no
energy besides Brownian motion, because it wanders where it is required within
reasonable time, does its job and then leaves.
Extracellular HMGB1 Signals to Multiple Cellular Targets
Although HMGB1 was considered to be a nuclear protein, biochemical and
immunological early studies performed by Bustin et al. suggested that its intracellular
distribution is not restricted to the nucleus and that in certain cells, HMGB1 was also
found in the cytoplasm [37]. It plays an important role in regulating cell migration,
inflammation and metastasis. Wang et al. identified HMGB1 as a late mediator of
endotoxin lethality in mice. These authors showed that monocytes/macrophages
stimulated by lipopolysaccharide (LPS), tumour necrosis factor (TNF) or interleukin-1
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(IL-1) secreted HMGB1 as a delayed response. In mice, injection of HMGB1 caused
toxic shock whereas administration of anti-HMGB1 antibodies attenuated LPS-induced
endotoxemia [38]. Sepsis is a systemic inflammatory response to bacterial products that
can lead to multiple organ failure and death. Septic patients have shown increased serum
level of HMGB1, which correlates with the severity of the infection. HMGB1 has also
been shown to cause acute lung inflammation when administered intratracheally.
Antibodies against HMGB1 decreased lung edema and neutrophile migration, whereas
they did not reduce the levels of the other proinflammatory cytokines TNF-α, IL-1β or
macrophage inflammatory protein-2 (MIP2). HMGB1 also participates in the regulation
of neuroendocrine and immune responses to inflammatory processes [39]. Extracellular
HMGB1 protein interacts with the extracellular matrix and the surrounding tissues and
with several cell surface receptors, including the receptor for advanced glycation end
products (RAGE) [40]. Necrosis is organ deterioration, whereas apoptosis is important
for organ maintenance and differentiation. HMGB1 serves as a signal that determines
whether cell death and injury will lead to necrosis or continue along a preintiated
apoptotic pathway [35].
Regulated Expression and Subcellular Localization of HMGB1
In transformed cell lines, HMGB1 is highly expressed at 106 molecules per cell,
which is 10 times less than histones. However, in intact organs, its expression is
developmentally regulated and/or responds to cues from the environment displaying an
amazing variation in expression pattern, level of expression, and subcellular location. The
HMGB1 gene is transcriptionally controlled by steroid hormones, using various signaling
pathways including the cytokine-activated JAK/STAT pathway [41]. It is also likely that
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other expression control, such as post-transcriptional controls of mRNA stability or
translation, and protein stability exist. Studies by Mosevitsky et al. looked at distribution
of HMGB1 in different mammalian tissues and found that lymphoid tissues and testis had
high HMGB1 levels in both nuclei and cytoplasm whereas brain and liver had low levels,
mainly in the cytosol [42]. These authors suggested that [HMGB1] is low in
differentiated cells, and high in undifferentiated cells. In intact mice, HMGB1 expression
is tightly regulated in the central nervous system [43, 44, 45]. In tumour cells, HMGB1
protein is found in higher level than in normal tissue of counterpart cells [46, 47].
HMGB2 and HMGB3, which are structurally similar to HMGB1, have similar
biochemical properties, but have a different expression pattern. These proteins are highly
expressed in the embryo, and both are expressed at very low levels in the adults [48, 49].
Hmgb2-/- mice are viable, and only show a marked reduction in spermatogenesis [41].
Hmgb3 knock-outs have not been described yet.
S. cerevisiae HMG-Box Proteins
S. cerevisiae contains ten HMG-box proteins, including the HMGB1/2 homologs
NHP6A/B, ~10 kDa proteins with a single HMG box, which have been shown to
participate in the RNA polymerase II and III transcription systems [50-53]. HMO1 and
HMO2 are ~25 kDa HMG-box proteins, also identified by homology-based motifprediction programs as having only a single HMG-box, in a position corresponding to the
HMG box B of mammalian HMGB. However, HMO1 also contains an N-terminal box A
domain with weak similarity to consensus HMG-box domains. The relative abundance of
NHP6A/B and HMO1/2 was recently determined as part of a global analysis of protein
expression in yeast. All four proteins are moderately abundant, with an estimated 1.9 x
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104 molecules of HMO1 per cell compared to ~4 x 103 for NHP6A/B and 1.8 x 103 for
HMO2 [54]. Strains bearing HMO1 or HMO2 mutant alleles are viable, although HMO1
mutant strains have growth defects, compromised plasmid maintenance and nuclease
sensitive chromatin, suggesting that HMO1 may play a role in stability of the chromatin
structure [55]. HMO1 has been shown to interact genetically and physically with
FKBP12 prolyl isomerase, a ubiquitous, highly conserved, abundant enzyme that
catalyzes a rate-limiting step in protein folding. Dolinski and Heitman [56] found that
mutations in HMO1 and in the FPR1 gene that encodes FKBP12 are synthetically lethal.
A recent study implicates HMO1 as part of the rRNA transcription apparatus, where it
was proposed to function in a similar capacity as the Upstream Binding Factor (UBF),
which is an auxiliary factor in the mammalian and amphibian RNA Polymerase I
transcription systems; UBF has six HMG domains [57]. HMO1 has also recently been
shown to participate in mutagenesis control, but its exact role remains to be elucidated.
The C terminus of HMO1 has a long run of basic residues not found in any other
HMGB1/2 protein. In vivo, the C terminus is dispensible for function whereas HMG Box
B is essential. As the basic C-terminus is predicted to harbor the nuclear localization
signal, the implication of this observation is that the growth phenotype characteristic of
the hmo1 knockout may be reversed by HMO1 mutant protein that is confined to the
cytoplasm. Immuno-localization experiments have shown that full length HMO1 is
present both in the nucleus and cytoplasm [55]. Although the biological significance of
the presence of HMO1 in the cytoplasm has not been established, it may serve the same
critical and diverse roles as does the extracellular HMGB1.
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We show here that the divergent box A domain does participate in direct DNA
contacts, and that it contributes modest structure-specific DNA binding to HMO1, while
box B confers most of the DNA binding affinity. Interestingly, unlike many HMGB
proteins that insert negative supercoils in the presence of topoisomerase I in topologically
closed DNA [51, 55], HMO1 did not supercoil relaxed closed circular DNA. We have
also shown that the HMO1 basic C-terminal tail participates in DNA binding, and that it
reduces the stability of the protein. Phosphorylation of HMO1 by casein kinase II lowers
its affinity for DNA, suggesting that HMO1 can be regulated by post-translational
modification. In vivo studies showed that HMO2 knockout has a slower growth
phenotype (contrary to a previous report [55]) which is only evident in the presence of an
HMO1 knockout, indicative of an overlap in function of these proteins. Using green
fluorescent protein (GFP), HMO1 was localized to the cytoplasm and the nucleus, while
HMO1 with the C-terminal domain deleted (M210) was localized only to the cytoplasm.
Previous studies [55] have shown that hmo1 knockouts transformed with the vector
carrying the M210 gene fully recovers to show wild type phenotype. This shows that the
essential and unique function of HMO1 protein is in the cytoplasm and not in the nucleus.
DNA Supercoiling by Vaccinia Topoisomerase I
DNA topoisomerases are ubiquitous enzymes that manage DNA topology in the
cell. They participate in a variety of cellular processes by solving the DNA topological
problems associated with replication, transcription, recombination, chromosome
condensation, decatenation and unknotting of DNA (reviewed in [59, 60]).
Topoisomerases fine-tune DNA topology to facilitate protein interactions with the DNA
which can be negatively affected by too much or too little supercoling. They alter DNA
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topology by the concerted cleavage and religation of DNA strand(s). The nucleophilic
attack of an active-site tyrosine on a phosphodiester DNA bond generates a
phosphotyrosyl linkage, providing a transient protein-linked gate through which another
DNA strand or duplex may pass. A second transesterification resolves the tyrosyl-DNA
linkage to restore DNA integrity [59, 60, 61].
With the recognition that topoisomerases play an important role in controlling
DNA topology, great interest has developed, especially due to the discovery of
topoisomerase targeted compounds. Clinically important anticancer and antibacterial
compounds that target topoisomerases are now in use. Camptothecin and its analogues
have shown remarkable antitumor activity against pediatric and adult malignancies [62].
Fluoroquinolones are compounds that target topoisomerases and are in wide clinical use
as antibacterial agents [63, 64, 65].
Classification of Topoisomerases
Topoisomerases are classified into subfamilies which are distinguished by
common biochemical properties and similarity in structure. While DNA cleavage by all
topoisomerases leads to formation of a transient covalent intermediate in which a tyrosine
is linked to a broken DNA strand, type II topoisomerases cleave both strands, which
results in DNA topoisomers differing in linking number in steps of two. They are further
divided into two different subfamilies based on structural considerations; type IIA and
IIB subfamilies. Type I topoisomerases relax supercoiled DNA, but unlike type II
topoisomerases, type I enzymes cleave only one strand and the linking number changes in
steps of one. They are also further classified as either type IA, if the protein link is to a 5′
phosphate or type IB, which form a covalent bond to a 3'-phosphate. Type I
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topoisomerases are found in all eukaryotes, where they relax both positive and negative
supercoils [59, 60, 61].
Cellular Roles of DNA Topoisomerases
Escherichia coli has four DNA topoisomerases, two type IA (DNA
topoisomerases I and III) and two type IIA enzymes (DNA gyrase and DNA
topoisomerase IV). Genetically, functional overlap of each enzyme has been shown
however, it appears that each enzyme has been optimized to carry out its own particular
set of topological manipulations. DNA gyrase is the only known topoisomerase that
generates negative supercoils by use of ATP as the energy source. As such, DNA gyrase
plays an important role in chromosome condensation leading to proper chromosome
partitioning at cell division [66, 67]. Any positive supercoils that are generated in the cell
during processes like transcription or replication are resolved by DNA gyrase.
Topoisomerase IV plays important roles in decatenation during replication [68] as well as
relaxing negative supercoils in the cell [69], along with topoisomerase I [70] to prevent
excessive negative supercoils generated by DNA gyrase or any other cellular processes
like transcription and replication.
In S. cerevisiae and Schizosaccharomyces pombe, topoisomerase I (IB subfamily)
is dispensable for growth, but topoisomerase IIA is required to decatenate linked
chromosomes and prepare them for segregation at mitosis [71, 72]. Topoisomerase II
relaxes supercoils of both signs and as such, it substitutes for topoisomerase I in its
absence. Deletion of topoisomerase III (type IA subfamily) in S. cerevisiae results in
slow growth exhibited by elevated levels of mitotic recombination. This deletion also
results in sporulation failure due to a defect in meiotic recombination [73, 74].
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In higher eukaryotes, topoisomerase I is indispensable during development and
during cell division [75, 76]. Higher eukaryotes contain two isoforms of topoisomerase II
and III termed α and β [59].
General Features of Type IA DNA Topoisomerase I
With the exception of the Methanopyrus kandleri encoded topoisomerase, all type IA
topoisomerases are monomeric, and they require Mg(II) for the DNA relaxation activity.
These proteins relax only negative

supercoils, but the relaxation does not go to

completion and they require an exposed single-stranded region within the substrate DNA
[59, 77]. These enzymes have been shown to catalyze the knotting, unknotting, and
interlinking of single-stranded circles as well as the knotting, unknotting, catenation, and
decatenation of gapped or nicked duplex DNA circles (reviewed in [59]). Although
considerable sequence diversity is observed in the type IA subfamily, E. coli
topoisomerase I, a prototype of this subfamily that is well studied, represents some
common features. The core cleavage/strand passage domain that is found at the Nterminal contains the active site tyrosine. Expression of this N-terminal fragment yields
a protein that retains the ability to cleave a single-stranded oligonucleotide, but is unable
to relax plasmid DNA [78]. This catalytic domain is followed by a Zn(II)-binding
domain. Although dispensable for activity in vitro, the C-terminal domain is rich in basic
amino acids and contributes to substrate binding with preference for a single-stranded
DNA [79, 80, 81]. In comparison to other type IA topoisomerases, both E. coli and S.
cerevisiae topoisomerase III lack a Zn(II) binding domain. Conversely, human
topoisomerase IIIα and IIIβ have a Zn(II) binding domain. It seems, however, that type
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IA topoisomerases possess a relatively basic C-terminal domain that although not
conserved, contributes to DNA binding.
General Features of Type IB DNA Topoisomerase
The type IB subfamily of topoisomerases is made up of three classes which
include eukaryotic topoisomerase I, poxvirus topoisomerase I and prokaryotic
topoisomerase V from M. kandleri [82, 83]. These proteins share structural and
functional properties with the tyrosine recombinases and some phage integrases [84].
Unlike type IA, type IB topoisomerases relax to completion both positive and negative
supercoils and as such, there is no need for exposed single-stranded region within the
substrate DNA. Type IB contains no bound metal ions, and DNA relaxation does not
require Mg(II). Human DNA topoisomerase I has four distinct domains; 1) the Nterminal domain which has nuclear localization signals and sites for interaction with other
proteins such as nucleolin and SV40, 2) the core domain which is highly conserved, binds
DNA and contains most of the catalytic residues except for the active site tyrosine, 3) the
linker domain which is poorly conserved and 4) the C-terminal domain which is
conserved and contains the active site tyrosine. Human topoisomerase I is proposed to
follow a “controlled rotation” mechanism for DNA relaxation, in which ionic interactions
between DNA and protein regulate the DNA winding process [85, 86].
The

poxvirus

topoisomerases

are

considerably

smaller

than

cellular

topoisomerases, are of fairly uniform size (314-333), and probably constitute the minimal
functional unit of a type IB topoisomerase. Vaccinia topoisomerase I is a 314-amino acid
protein that binds to duplex DNA with stringent specificity for transesterification at DNA
sites containing the sequence 5'-(C/T)CCTT↓ [87-91]. The 3' phosphate of the incised
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strand is linked to Tyr-274 of the enzyme. Vaccinia topoisomerase I consists of two
structural domains joined through a trypsin-sensitive bridge. The N-terminal domain
(amino-acids 1-80), which is highly conserved in poxvirus and vertebrate topoisomerases,
contacts the-(C/T)CCTT DNA site in the major groove [92, 93]. The C-terminal domain
(amino-acids 81-314) comprises an autonomous catalytic domain that performs the same
repertoire of reactions as the full-sized topoisomerase I [94, 95]: relaxation of supercoiled
DNA, site-specific DNA transesterification, and DNA strand transfer [94]. The structure
of the catalytic domain is similar to that of human topoisomerase I except for a
displacement of the active site tyrosine [71, 95]. The catalytic domain is also very similar
to core domain III and a 19 amino acid region encompassing the active site of human
topoisomerase I.
Fluoroquinolone Compounds
Since the first quinolone nalidixic acid was developed, the quinolones have
undergone structural modifications, in particular the addition of a fluorine at position 6,
to produce the fluoroquinolones (reviewed in [67]). This has seen their potency and
pharmakokinetic profile greatly increase. Fluoroquinolones are topoisomerase II poisons
known to target DNA gyrase and topoisomerase IV in bacterial cells [64, 65, 96]. The
interaction of norfloxacin with the DNA-gyrase complex has been investigated in some
detail. While binding of norfloxacin to gyrase was undetectable, it was shown to bind
DNA directly and to exhibit a binding mode involving preferred recognition of singlestranded DNA. Drug binding was enhanced by the presence of gyrase, suggesting that
DNA-binding revealed a cryptic norfloxacin binding site on the enzyme [97, 98]. The
nature of the norfloxacin-DNA complex has been analyzed by several groups, with
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somewhat disparate conclusions. Norfloxacin was reported to require magnesium ions for
DNA binding, with Mg2+ proposed to act as a bridge between the negatively charged
DNA phosphates and the carbonyl and carboxyl moieties of norfloxacin [99]. However,
more recent reports showed binding of norfloxacin to DNA in the absence of Mg2+ and
suggested a mode of DNA interaction that ruled out classical DNA intercalation or
groove binding, based in part on the observation that the molecular plane of norfloxacin
is nearly perpendicular to the helix axis [100-101]. These authors also found that DNA
unwinding by norfloxacin is negligible and proposed instead that the compound may
induce a bend in the DNA helix.
The inhibitory effect of fluoroquinolones is based on their ability to stimulate the
forward rate of the topoisomerase II-mediated DNA scission; after binding the cleavable
complex, the fluoroquinolone induces a conformational change in the enzyme that
prevents religation [102-104]. The replication fork is blocked by the stabilization of these
complexes, resulting in irreversible DNA-enzyme complexes, which probably leads to
lethal release of double-stranded DNA breaks [63, 64, 105, 106].
The fluoroquinolone derivative ofloxacin was previously shown also to exhibit
antiviral activity against Vaccinia virus, and the inhibitory activity shown to correlate
with inhibition of topoisomerase I purified from Vaccinia virus cores [107]. Therefore,
with wider screening of these fluoroquinolone compounds, it is likely to result in
discovery of compounds with antiviral activity or compounds that can be optimized or act
as a lead to more potent antiviral agents.
Here we describe a novel interaction of enrofloxacin with Vaccinia topoisomerase
I in vitro. Enrofloxacin, a fluoroquinolone antibiotic which targets DNA gyrase and
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topoisomerase IV in bacterial cells inhibits DNA relaxation by Vaccinia topoisomerase I
in a concentration dependent fashion. In the presence of relaxed DNA, however,
enrofloxacin causes Vaccinia topoisomerase I to supercoil DNA, reversing its action as a
DNA relaxing enzyme. Further characterization indicates that enrofloxacin does not
interfere with the initial strand scission by Vaccinia topoisomerase I, nor does it interfere
with enzyme’s ability to bind DNA. The mechanism with which Vaccinia topoisomerase
I supercoils relaxed DNA, an energetically unfavorable, yet ATP-independent process,
must entail protein-DNA contacts downstream of the cleavage site, as opposed to the free
rotation mechanism proposed for DNA relaxation. In cell culture, enrofloxacin and
several other fluoroquinolone compounds inhibited Vaccinia virus.
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CHAPTER 2
THE SACCHAROMYCES CEREVISIAE HIGH MOBILITY GROUP BOX
PROTEIN HMO1 CONTAINS TWO FUNCTIONAL DNA BINDING DOMAINS
Introduction
High-mobility group (HMG) proteins constitute a significant proportion of nonhistone proteins of eukaryotic chromatin. They are abundant proteins that are grouped
into three major classes, in part based on their DNA-binding characteristics: HMGA,
HMGB, and HMGN [1-4]. HMGB proteins contain one or more homologous repeats of
the ~80-amino acid sequence HMG box and are classified into two families based on the
abundance, function and DNA specificity of this conserved region [1, 5, 6]. The
moderately sequence-specific family is typified by transcription factors such as sexdetermining factor SRY and lymphoid enhancer factor LEF-1 [7, 8], while the nonsequence-specific family is represented by so-called architectural factors HMGB1/2 and
the Saccharomyces cerevisiae non-histone chromosomal proteins 6A and 6B (NHP6A/B)
[9].
The tertiary structures of HMG boxes from sequence-specific and non-sequencespecific proteins have revealed an evolutionarily conserved, common global fold
consisting of an L-shaped structure composed of three α-helices [10-19]. The HMG DNA
binding domain, which interacts with ~10 bp of duplex, binds to the minor grove of DNA
by partial intercalation of one or two surface-exposed, conserved hydrophobic residues
into the base pair stack. Consequently, the DNA is greatly distorted, resulting in a sharp
bend and helical underwinding [4, 8, 14, 16, 20]. SRY and LEF-1 cause bending by
insertion of helix I hydrophobic residues Ile and Met, respectively, into the base pair
Reprinted from Journal of Biological Chemistry vol 279. Copyright 2004, The American Society for
Biochemistry and Molecular Biology, Inc
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Figure 2.1 Alignment of HMG-box helices I and II. For non-sequence specific proteins,
box A and box B of rat HMGB1 is shown along with S. cerevisiae NHP6A, Drosophila
melanogaster HMGD and S. cerevisiae HMO1. The HMO1 box B insertion is indicated
in lower case. Sequence specific proteins are human SRY, mouse LEF-1 and Xenopus
laevis UBF box A. Residues corresponding to positions 16 and 37 of HMGB1 helices I
and II, respectively, are in bold.
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stack (Figure 1[ 8, 17]). HMGB1 contains tandem HMG box domains referred to as box
A and box B; DNA-intercalating residues are located at positions 16 and 37 of helices I
and II, respectively, and both can contribute to binding affinity [11, 13, 16, 19]. HMGB
proteins recognize DNA with structural specificity, binding preferentially to distorted
DNA such as 4-way junctions, mini-circles, and cisplatinated DNA, and they supercoil
relaxed, topologically closed DNA in the presence of topoisomerase I [11, 16, 20-25].
HMGB proteins have been implicated in diverse biological processes such as
transcription, recombination, replication and DNA repair by virtue of their ability to
facilitate assembly of nucleoprotein complexes [1, 3, 5].
S. cerevisiae contains ten HMG-box proteins, including the HMGB1/2 homologs
NHP6A/B, ~10 kDa proteins with a single HMG box, which have been shown to
participate in the RNA polymerase II and III transcription systems [9, 26-28]. HMO1 and
HMO2 are ~25 kDa HMG-box proteins, also identified by homology-based motifprediction programs as having a only single HMG-box, in a position corresponding to
box B of mammalian HMGB. However, HMO1 also contains an N-terminal box A
domain with weak similarity to consensus HMG-box domains (Figure 1). The relative
abundance of NHP6A/B and HMO1/2 was recently determined as part of a global
analysis of protein expression in yeast. All four proteins are moderately abundant, with
an estimated 1.9 x 104 molecules of HMO1 per cell compared to ~4 x 103 for NHP6A/B
and 1.8 x 103 for HMO2 [29]. Strains bearing HMO1 or HMO2 mutant alleles are viable,
although HMO1 mutant strains have growth defects, compromised plasmid maintenance
and nuclease sensitive chromatin, suggesting that HMO1 may play a role in stability of
the chromatin structure [30]. HMO1 has been shown to interact genetically and
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physically with FKBP12 prolyl isomerase, a ubiquitous, highly conserved, abundant
enzyme that catalyzes a rate-limiting step in protein folding. These authors found that
mutations in HMO1 and in the FPR1 gene that encodes FKBP12 are synthetically lethal
[31]. A recent study implicates HMO1 as part of the rRNA transcription apparatus, where
it was proposed to function in a similar capacity as the Upstream Binding Factor (UBF),
which is an auxiliary factor in the mammalian and amphibian RNA Polymerase I
transcription systems; UBF has six HMG domains [32]. HMO1 has also recently been
shown to participate in mutagenesis control, but its exact role remains to be elucidated
[33].
We show here that the divergent box A domain does participate in direct DNA
contacts, and that it contributes modest structure-specific DNA binding to HMO1, while
box B confers most of the DNA binding affinity. HMO1 displays a longer residence time
on constrained DNA minicircles, consistent with its role in the maintenance of chromatin
structure.
Experimental Procedures
Cloning and Purification of Proteins
The gene encoding HMO1 was amplified from yeast genomic DNA using primers
modified to introduce NdeI sites at both ends of the PCR product; forward primer, 5′GCCTGTCACCATATGACTACAG-3′,

reverse

primer,

5′-

AGTAACGCATATGTCCGTCC-3′ (NdeI sites underlined). The HMO1 gene was
cloned into the NdeI site of plasmid pET5a, and plasmid carrying the HMO1 gene was
transformed into E. coli BL21(DE3)pLysS. HMO1 expression was induced by addition
of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at an OD600 of 0.4 and the culture
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incubated for 3 h. Cells were pelleted and resuspended in lysis buffer (50 mM Tris-HCl
pH 8.0, 1 M NaCl, 5% glycerol, 5 mM EDTA, 1 mM 2-mercaptoethanol, 1 mM phenyl
methyl sulfonyl fluoride (PMSF)). Cells were disrupted by sonication and nucleic acids
digested by addition of DNase I followed by a one-hour incubation on ice. The extract
was clarified by centrifugation at 5000 × g for 20 min. The supernatant was dialyzed
overnight against HA buffer pH 8.7 (20 mM Tris-HCL, 50 mM KCl, 10% glycerol, 1
mM EDTA, 4 mM 2-mercaptoethanol, and 1 mM PMSF). The dialysate was passed
through tandem columns of DEAE-cellulose and CM-sepharose equilibrated with the
same buffer. Proteins were eluted with a 120 ml linear gradient from 50 mM KCl (HA
buffer) to 1 M KCl (HB buffer; 20 mM Tris-HCl, 1 M KCl, 10% glycerol, 1 mM EDTA,
4 mM 2-mercaptoethanol, 1 mM PMSF). Peak fractions were collected, dialyzed
overnight in HA buffer pH 8.7, and passed through a Heparin column equilibrated with
the same buffer and proteins were eluted and analyzed as described above. Peak fractions
were collected and dialyzed overnight in HA buffer pH 7.0. The dialysate was passed
through CM-sepharose equilibrated with the same buffer and proteins were eluted and
analyzed as described above. Pure HMO1 fractions were concentrated and quantitated on
Coomassie Blue stained SDS-PAGE gels using BSA as a standard.
The gene encoding HMO1 was also subcloned into pET28b for expression with
an N-terminal His6-tag. Using a PCR-based site-directed mutagenesis approach, a stop
codon was inserted into the HMO1 gene in place of Pro91 to create the truncated protein
HMO1-BoxA, lacking box B and the basic tail region, using primers forward, 5'CGCTGCTTGAGTCAAGGCT-3',

and

reverse,

5'-

ATAATAGCATCTTTATCATCATCAATAGGG-3'. Plasmids, HMO1-pET28b and
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BoxA-pET28b, were transformed into E. coli Rosetta Blue. Cultures were grown to an
OD600 of 0.2 and expression was induced with 1mM IPTG for 3 h. Cells were pelleted,
resuspended in a dialysis/lysis buffer pH 7 (50 mM NaxHyPO4, 300 mM NaCl, 10 mM
imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF), disrupted by
sonication, and nucleic acids digested by addition of DNase I followed by a one-hour
incubation on ice. The lysate was dialyzed overnight in dialysis/lysis buffer. The
dialysate was passed through a Ni-NTA column equilibrated with dialysis/lysis buffer
and washed with 5 column volumes of wash buffer pH 7 (50 mM NaxHyPO4, 300 mM
NaCl, 20 mM imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF).
Proteins were eluted with a 50 ml linear gradient from 20 mM imidazole (wash buffer) to
250 mM imidazole (elution buffer: 50 mM NaxHyPO4, 300 mM NaCl, 250 mM
imidazole, 10% glycerol, 1 mM 2-mercaptoethanol, and 1 mM PMSF) followed by 100
ml of elution buffer. Pure HMO1 and HMO1-BoxA fractions were quantitated on
Coomassie Blue stained SDS-PAGE gels using BSA as a standard. Bacillus subtilis HU
was cloned from B. subtilis genomic DNA and overexpressed in E. coli. Detailed
procedures for its cloning and purification will be reported elsewhere.
Circular Dichroism Spectroscopy
CD spectra were recorded on an AVIV Model 202 CD spectrophotometer using a
1 cm pathlength sample cell. Wavelength scans from 200 nm to 240 nm were performed
in triplicate, and data points were averaged and smoothed using standard methods. The
wavelength scan for His6-tagged HMO1 was recorded at 25ºC, with a protein
concentration of 0.025 mg/ml in 2.5 mM NaxHyPO4, pH 7.0, 0.5% glycerol, 10 mM
NaCl. The wavelength scan for His6-tagged HMO1-BoxA was recorded at 4ºC, using a
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protein concentration of 0.05 mg/ml in 1 mM Tris, pH 7.0, 0.03% Tween 20, 10%
glycerol, 2.8 mM KCl.
Ligase-Mediated Circularization
Ligation substrates were prepared by digestion of PCR amplified or plasmid
DNA with appropriate endonucleases. pET5a was digested with BamHI and BgIII to
generate a 136 bp fragment while BspHI digestion generated a 105 bp fragment. An 87
bp fragment was generated by digestion of pcDNA3 with SacI. A 75 bp DNA fragment
was generated by PCR amplification of the 390-538 bp region of pUC18 using Taq
polymerase

and

primers

5′-GCCAGTGCCAAGCTTGCATG-3'

and

5′-

CTTTATGCTCTCGAGTCGTATGTT-3′, followed by digestion with SacI. DNA
fragments were purified on 7% (w/v) polyacrylamide gels and 5'-end labeled with T4
polynucleotide kinase and ( -32P) ATP. Reactions were initiated by addition of 20 units
of T4 DNA ligase to a final volume of 100 µl reaction buffer (20 mM Tris-HCl pH 8, 50
mM NaCl, 10 mM MgCl2, 0.1 mM Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing
1200 fmol DNA, with or without HMO1. Time points were taken over 90 minutes. For
each time point, 8 µl of the reaction mixture was quenched by addition of 5 µl stop buffer
(75 mM EDTA, 15% glycerol, 0.1%bromophenol blue (BPB), 0.1%xylene cyanol, 6
µg/µl proteinase K). Samples were heated at 55°C for 15 minutes and resolved on prerun
7% (w/v) native polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with
0.5X TBE (50 mM Tris-borate, 1 mM EDTA). Quantitation was performed on a
Molecular Dynamics Storm Phosphorimager using software supplied by the
manufacturer.
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DNA Supercoiling
Reactions contained 0.2 µg relaxed closed circular pUC18 plasmid, prepared by
adding 2.5 units of Vaccinia topoisomerase I (Epicenter) to supercoiled pUC18 in 50 mM
Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM EDTA. After 1.5 h at 37°C,
varying amounts of HMO1 were added and the reactions incubated for 1 h at 37°C.
Reactions were quenched with 5 µl termination buffer (5X TBE, 5% SDS, 15% sucrose,
0.1%BPB, 0.1%xylene cyanol, 2 µg/µl proteinase K) and incubated for 1 h at 37°C.
Samples were loaded on 1% 1X TBE agarose gels and electrophoresed at 2 V/cm for 12 h
in 1X TBE buffer.
Agarose Gel Retardation
Reactions were incubated at room temperature in 10 µl reaction buffer containing
0.2 µg linear, relaxed closed circular or supercoiled pUC18 and varying amounts of
HMO1 or HMO1-BoxA. Complexes were resolved on 0.7% 1X TAE agarose gels and
electrophoresed at 2.5 V/cm for 3 h in 1X TAE buffer (40 mM Tris-acetate, 1 mM
EDTA, pH 8.0). Gels were stained with ethidium bromide after electrophoresis.
Electrophoretic Mobility Shift Assays (EMSA) with DNA minicircles
The 105 bp fragment generated by BspHI digestion of pET5a DNA was 5'-end
labeled with T4 polynucleotide kinase and ( -32P) ATP. DNA minicircles were generated
by intramolecular ligation of the 32P-labeled 105 bp DNA fragment with 20 units of T4
DNA ligase in the presence of Thermotoga maritima HU for 2 h at room temperature
(34). Samples were treated with Exonuclease III for 1 h at room temperature and the
reactions quenched with stop buffer. The de-proteinised DNA was purified on a 6% (w/v)
native polyacrylamide gel (39:1 acrylamide:bisacrylamide).
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EMSA was performed with linear and circular 105 bp DNA. Reactions were
incubated at room temperature in 10 µl reaction buffer containing 5 fmol DNA and
varying amounts of HMO1. Where indicated, reactions were performed in the absence of
MgCl2. Samples were resolved on prerun 7% (w/v) native polyacrylamide gels (39:1
acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE running buffer. Complexes were
visualized by phosphorimaging. In DNA competition assays, 10 fmol of
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P-labeled

linear or circular 105 bp DNA was incubated with HMO1 for 30 min at room temperature
to allow complex formation, followed by addition of varying amounts of linear pUC18
plasmid DNA. Samples were resolved as described above. For calculating fractional
complex formation, the region on the gel from the slowest migrating complex to the free
DNA was considered as complex.
EMSA with Four-Way DNA Junctions
Four-way junctions were constructed using a published protocol [35]; the
sequence of individual strands was as described [36]. The 4-way junction was prepared
by annealing the four strands, followed by purification of the junctions on native
polyacrylamide gels. To ensure that all oligonucleotides were present, aliquots of the
purified junctions were run on denaturing gels. EMSA were performed as described
above with 5 fmol DNA and varying amounts of HMO1 or HMO1-BoxA; for
experiments with HMO1-BoxA, the reaction buffer was modified to contain only 25 mM
NaCl, MgCl2 was omitted, and 0.5% Tween 20 was included. In competition assays, 20
or 1000-fold mass excess of unlabeled linear pUC18 DNA was added after the addition
of HMO1. Complexes were resolved and quantified as described above.
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EMSA with linear duplex DNA and DNA Containing Loops, Nicks, Gaps or Overhang
Oligonucleotides were purchased and purified by denaturing gel electrophoresis.
Oligonucleotides used to generate constructs with loops, nicks, gaps or overhangs
included

a

common

37

nt

top

strand:

5′-

CCTAGGCTACACCTACTCTTTGTAAGAATTAAGCTTC-3′. To generate 37 bp
duplex DNA, complementary oligonucleotides were mixed at equimolar concentrations,
heated at 90° C, and slowly cooled to room temperature. To generate looped DNA, a
complementary strand with a pair of 2-nt mismatches with 11 nt spacing (3′GGATCCGATGCCATGAGAAACATAGTTAATTCGAAG-5′,

with

mismatched

nucleotides indicated in bold) was annealed to the top strand. A spacing of 11 bp was
chosen as it represents the spacing that yielded optimal complex formation with
mammalian HMGB1 [37]. The 37 bp DNA with a central nick, gap, or a 3'-overhang
were prepared as described [36]. The 18 bp duplex corresponded to the sequence of the 5'
half of the 37 bp duplex. The sequence of the 26 bp duplex was: 5'CGTGACTACTGTAAGTCGATGATCCG-3'. EMSA were performed as described
above with 5 fmol DNA. The observed fraction of complex formation was corrected for
dissociation during electrophoresis, and binding isotherms for HMO1 binding to 26 bp
DNA was fitted as described [36]. All experiments were done at least in triplicate, and
values are reported as the mean ± standard deviation.
Competition assays involving HMO1-BoxA were performed with
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P-labeled 26

bp DNA. Reactions were incubated at room temperature in 10 µL reaction buffer
containing 10 fmol of DNA, 400 fmol B. subtilis HU or 4 pmol full-length HMO1, and
varying amounts of HMO1-BoxA. B. subtilis HU or HMO1 was incubated with DNA at
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room temperature for 5 min, followed by addition of HMO1-BoxA. Samples were
resolved on prerun 7% native gels at 4°C with 0.5X TBE running buffer. Complexes
were visualized by phosphorimaging.
Results
DNA binding by HMO1 and HMO1-BoxA
Recombinant HMO1 and His6-HMO1 were purified to apparent homogeneity, as
judged by Coomassie Blue-staining of SDS-PAGE gels. For analysis of DNA binding by
the divergent box A domain, N-terminally His6-tagged HMO1-BoxA was also prepared
(Figure 2.2A). CD spectra of both full-length HMO1 and HMO1-BoxA are characterized
by negative ellipticities at 208 and 222 nm, indicative of significant α-helical content
(Figure 2.2B-C). The qualitatively comparable spectra suggest that HMO1-BoxA is an
independently folded domain. The previously reported ability of HMO1 to self-associate
[31], evident at higher protein concentrations, was also characteristic of the box A
domain for which well-resolved CD spectra required the presence of detergent.
DNA binding was analyzed with Electrophoretic Mobility Shift Assays (EMSA).
While no stable complex could be seen on incubation of 18 bp DNA with full-length
HMO1 (data shown), a single complex formed with 26 bp DNA (Figure 2.3). No
difference was seen between N-terminally His6-tagged and untagged HMO1 (data not
shown; all subsequent experiments were performed with untagged HMO1). The apparent
dissociation constant Kd for HMO1 binding to 26 bp DNA is 39.5 ± 5.0 nM. HMO1
forms two complexes with 37 bp DNA (Figure 2.4A), as seen previously with the
mammalian two-HMG box protein HMGB1 [37], suggesting similar site sizes. Halfmaximal saturation is observed at 33.1±3.9 nM HMO1. For reactions performed in the
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Figure 2.2 HMO1 and HMO1-BoxA have significant α-helical content. (A) SDSPAGE gels showing purified His6-HMO1 (left) and His6-HMO1-BoxA (right). (B)-(C)
CD spectra of HMO1 and HMO1-BoxA, respectively.
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Figure 2.3 Electrophoretic analysis of 26 bp DNA titrated with HMO1. (A) Reactions
contain 5 fmol DNA. Reactions in lanes 2-14 contain 6, 12, 24, 48, 72, 96, 120, 144, 188,
192, 216, 240, and 264 nM HMO1. (B) Binding isotherm for HMO1 binding to 26 bp
DNA. When error bars are not shown, they are smaller than the symbol size. Inset shows
purified untagged HMO1 (lane 2). Molecular weight markers are identified at the left (in
kDa).
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Figure 2.4 Binding of HMO1 and B. subtilis HU to 4-way junctions and linear duplex
DNA. (A) HMO1, (B) B. subtilis HU. Reactions contain 5 fmol DNA, and protein
concentrations are 0, 1, 2, 4, 8, 16, 24, 28, 32, 36, 40 and 60 nM (identical for all panels).
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absence of Mg2+, the affinity is slightly higher with half-maximal saturation of 15.6±2.3
nM (data not shown). The lower affinity measured in the presence of magnesium ions
may not be due to effects caused specifically by the divalent ions, but a general effect of
raised ionic strength.
While no complex is detected upon incubation of 26 bp DNA with HMO1-BoxA,
a competition experiment in which full-length HMO1 is incubated with 26 bp DNA in the
presence of increasing concentrations of HMO1-BoxA shows a reduction in HMO1-DNA
complex formation, suggesting that HMO1-BoxA competes for binding to the DNA (data
not shown). However, since HMO1-BoxA self-associates, this experiment does not
exclude the possibility that HMO1-DNA complex formation is impaired due to
interactions between HMO1-BoxA and full-length protein. The competition experiment
was therefore also performed using the unrelated architectural protein HU from Bacillus
subtilis (Figure 2.5A). Consistent with DNA binding by HMO1-BoxA, HU-DNA
complex formation is also reduced in the presence of HMO1-BoxA. Efficient competition
requires µM concentration of HMO1-BoxA, suggesting low-affinity binding, consistent
with HMO1-BoxA complexes with 26 bp DNA being too unstable to detect following
electrophoresis.
HMO1 and HMO1-BoxA have only limited preference for distorted DNA
HMGB proteins have been shown to recognize distorted DNA structures
selectively [21, 24, 35, 37, 38]. Compared to linear duplex DNA, however, HMO1 did
not show binding preference for DNA with loops, nicks, gaps or overhangs (data not
shown); by comparison, the 37 bp looped DNA construct served as a preferred substrate
for mammalian HMGB1 [37]. Evidently, intrinsic DNA flexibility does not confer a
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Figure 2.5 HMO1-BoxA binds DNA. (A) HMO1-BoxA competes with B. subtilis HU
for binding to 26 bp DNA. Reactions contain 10 fmol DNA and 50 nM HU (lanes 2-8).
Reactions in lanes 3-8 contain 0.2, 0.4, 0.9, 8.8, 17.6, and 26.4 µM HMO1-BoxA. (B)
Electrophoretic analysis of HMO1-BoxA binding to 4-way junction DNA (5 fmol).
Reactions in lanes 2-7 contain 2.2, 11, 22, 33, 44, and 66 µM HMO1-BoxA.
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significant energetic advantage for HMO1 to bind DNA. Surprisingly, HMO1 also had
only limited preference for 4-way junctions (Figure 2.4A). Half-maximal saturation is
observed at 19.6±2.2 nM of HMO1 and for reactions performed in the absence of Mg2+,
half-maximal saturation is 6.1±1.1 nM. This is in distinct contrast to other HMGB
proteins which were shown to bind 4-way junction DNA only in the open square
conformation that is preferred in the absence of Mg2+ [39]. For comparison, B. subtilis
HU showed the expected preference for the 4-way junctions compared to linear DNA
with a sequence that corresponds to the longest arms of the 4-way junctions, confirming
integrity of the 4-way junction construct (Figure 2.4B). As shown in Figure 5B, HMO1BoxA also exhibits a modest preference for 4-way junction DNA; consistent with selfassociation of HMO1-BoxA, stable complex formation is enhanced by the presence of
detergent. Notably, the formation of detectable complexes with a migration pattern
similar to that seen for full-length HMO1 confirms the ability of HMO1-BoxA to engage
DNA directly.
When HMO1 was added to reaction mixtures containing both 4-way junction and
linear duplex DNA, HMO1 bound with only modest preference to the 4-way junctions
(Figure 2.6). In competition assays, EMSA was performed with either 32P-labeled 4-way
junctions or 32P-labeled linear duplex DNA in the presence of unlabeled competitor linear
or supercoiled plasmid DNA. HMO1 was competed off the linear and 4–way junction
DNA equally efficiently by linear and supercoiled plasmid DNA (data not shown). These
assays indicate that HMO1 does not have significant preference for supercoiled compared
to linear plasmid DNA. To investigate the interaction of HMO1 with different DNA
topologies further, agarose gel retardation assays were performed with negatively
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Figure 2.6 HMO1 has only modest preference for 4-way junction DNA. Reactions
contain linear duplex DNA and 4-way junctions. HMO1 was added at increasing
concentrations, ranging from 10 nM to 120 nM.
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supercoiled, relaxed and linear pUC18 plasmid. As shown in Figure 2.7, HMO1 has only
modest preference for supercoiled DNA. Regardless of DNA topology, HMO1 causes the
entire population of DNA to shift as a rather broad band, suggesting that HMO1 binds
without cooperativity. Consistent with its low-affinity binding to 26 bp DNA, HMO1BoxA does not form complexes with plasmid DNA that are detectable following
electrophoresis (data not shown).
HMO1 exhibits a longer residence time on DNA minicircles
DNA mini-circles are circularized DNA shorter than the persistence length of
∼150 bp. Since the DNA is highly constrained, a diminished need for DNA distortion
may lower the free energy of interaction. HMO1 bound 105 bp circular DNA comparably
to 105 bp linear DNA (Figure 2.8A). However, in DNA competition assays with linear
pUC18 plasmid, HMO1 was more efficiently competed off linear 105 bp DNA; at 400fold excess plasmid DNA, HMO1 still bound 91% of the 105 bp circular DNA as
opposed to only 13% of the linear 105 bp DNA (Figure 8B), suggesting a much longer
residence time on the constrained minicircle.
HMO1 bends DNA
Ligase-mediated circularization assays were performed in which the efficiency
with which T4 DNA ligase mediates ring closure of DNA fragments that are shorter than
the persistence length is measured [20, 40]. The ability of HMO1 to enhance ligasemediated DNA circularization was qualitatively assessed with 136, 105, 87, 75 and 65 bp
duplex DNA. HMO1 facilitated formation of circles with DNA of 136, 105 and 87 bp,
but not 75 or 65 bp (Figure 2.9).
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Figure 2.7 Binding of HMO1 to supercoiled, relaxed and linear DNA. Lanes 1, 8 and
15 with no HMO1 and lanes 2-7, 9-14 and 16-21 with increasing amounts of HMO1
(1250 fmol-7500 fmol). Samples were analyzed on 0.7% agarose gels.
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Figure 2.8 (A) Binding of HMO1 to linear and circular 105 bp DNA. EMSA with 10
fmol DNA. Lanes 2-6 and 8-12 contain 2.5, 10, 25, 50, 75 nM HMO1 respectively. (B)
DNA competition assay. HMO1 (5 pmol) was incubated with 10 fmol linear (left panel)
or circular (right panel) 105 bp DNA and titrated with unlabeled linear pUC18 DNA.
Lanes 3, 4, 5 and 8, 9, 10 contain 4, 40 and 400-fold excess of pUC18, respectively.
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Figure 2.9 (A) Time-course ligation assay with 87 bp DNA. 100 fmol 87 bp linear
DNA was incubated without (left panel) or with HMO1 (250 nM, right panel) up to 96
minutes. Time points were taken at 6, 12, 24, 48, 72 and 96 min. Exonuclease III was
added to reactions in lane 7 and 14 at 48 min time-points. Circular ligation products (lane
14) were resistant to digestion by Exonuclease III. (B) Quantitation of ligation assays for
136, 105 and 87 bp DNA. Effective concentrations of monomeric DNA differ for the
three substrates, particularly for the 105 bp DNA for which formation of 210 bp dimer
circles predominates. Initial rates therefore do not correlate with duplex length.
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As expected, initial rates of cyclization are highest for the longer 136 bp DNA, however,
the 87 bp DNA produced monomer circles most efficiently. Dimer circle formation and
multimerization of the 87 bp DNA occurred in reactions with and without HMO1,
although to a lesser extent compared to the other DNA constructs. The 105 bp DNA
yielded the least efficient monomer circle formation, however, more than 50% of the
DNA formed dimer circles even in the absence of the protein, lowering the effective
concentration of monomeric DNA and causing the initial rate and net yield of monomer
circles to be lower than that measured with 87 bp DNA. Secondly, the different cohesive
termini of the DNA probes are recognized differentially by DNA ligase. By comparison,
S. cerevisiae non-histone protein 6A (NHP6A) can form monomer circles with DNA
substrates of 66 bp [20] while HMGB1/2 and HMG-D can form monomer circles with
DNA substrates as short as 59 and 55 bp, respectively, at high protein concentrations [41,
42]. The protein concentrations used in our experiments are comparable to the
concentrations used for other HMGB proteins; our data therefore indicate that HMO1
bends DNA, although not as effectively as other HMGB proteins.
HMO1 does not supercoil relaxed DNA
Many HMGB proteins insert negative supercoils in the presence of topoisomerase
I in topologically closed DNA [25, 30, 43]. To assess the ability of HMO1 to supercoil
DNA, relaxed closed circular pUC18 DNA was incubated with increasing amounts of
HMO1 (Figure 2.10). There was no evidence of DNA supercoiling by HMO1, nor did
HMO1-BoxA supercoil DNA (not shown). This contrasts with a previous publication by
Lu et al. who, focusing on analysis of HMO1 purified from yeast, reported that HMO1
could indeed supercoil relaxed plasmid DNA [30].
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Figure 2.10 HMO1 does not supercoil relaxed DNA. Lanes 1 and 2 contain supercoiled
(S) and relaxed (R) pUC18 DNA, respectively. Increasing amounts of HMO1 (1250
fmol-7500 fmol) in lanes 3-6 and Bsu HU (1250 fmol-7500 fmol) in lanes 7-10 were
added to relaxed circular DNA.
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Discussion
Recent studies have shown that the difference between sequence-specific HMGB
proteins and the non-sequence specific homologs depends on individual DNA
intercalating residues and the global features of the HMG box, which determines the
mode of DNA recognition. For the tandem HMG boxes of HMGB1, the DNA
intercalating residues are at positions 16 or 37, located in helices I and II respectively,
and both can contribute to the binding affinity of the HMG boxes. Box A has an alanine
at position 16, which does not intercalate with the DNA but forms a hydrophobic contact,
whereas phenylalanine at position 37 is used as a bending wedge (Figure 2.1). Box B has
a phenylalanine at position 16 and isoleucine at position 37, both of which are potential
intercalating residues. Sequence-specific HMGB proteins have polar residues at position
37, which participate in sequence-specific hydrogen-bond formation [8, 16, 42, 44]. For
both box A and B of HMGB1, their ability to bend DNA is reflected in preferred binding
to distorted DNA. Box B, with its two DNA-intercalating residues, introduces the
greatest bend, whereas box A fails to bend DNA effectively [41, 45]. Box A has the
greatest preference for distorted DNA due to stacking of the helix II bending wedge on an
exposed base pair, whereas the affinity of box B for distorted DNA is only modestly
greater than its affinity for duplex DNA [45, 46]. Accordingly, the presence of a
hydrophobic DNA intercalating residue in position 16 of helix I appears to be important
for bending, while a bending wedge in helix II may be required for selective recognition
of distorted DNA.
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We have found HMO1 to bend DNA but to have only modest preference for
distorted DNA structures, including the 4-way junction. The HMO1 box A domain is
highly divergent from the consensus, containing a five amino acid insertion in the middle
of helix III, including a helix-breaking glycine that is likely to affect its structure and
mode of DNA interaction. However, our data show that the box A domain has significant
α-helical content, consistent with an HMG-like fold, and that it is involved in direct DNA
contacts (Figures 2.2 and 2.5). DNA bending by HMO1 would be consistent with the
presence of hydrophobic residues in position 16 of both HMG boxes and the potential use
of I37 of box A as an additional bending wedge. The limited preference of HMO1 for
distorted DNA, combined with the low-affinity binding of HMO1-BoxA that is also only
modestly enhanced by the presence of pre-bent DNA conformations, suggests that box A
contributes the modest structure-specificity, while box B, which has no hydrophobic
residue at position 37, confers most of the DNA binding affinity. The contribution of box
A to DNA interactions is also consistent with the occluded site size for HMO1, which
fails to form a stable complex on 18 bp DNA, but which forms two complexes on 37 bp
DNA (Figure 2.4) as also seen for the mammalian two-HMG box protein HMGB1 [37].
Ligase-mediated circularization of small DNA fragments has been extensively
utilized as a means of comparing the DNA bending activities of non-sequence specific
DNA bending proteins. Both HMGB1/2 and NHP6A/B catalyze formation of 66 bp
circles, although NHP6A/B are more efficient [13, 41, 47]. This high efficiency has been
attributed to the relative stability of NHP6A/B-DNA complexes compared to HMGB1/2
and HU complexes [13, 41], but could also be due to a difference in the bend angle
exerted by these proteins, with the angle exerted by NHP6A/B facilitating DNA strand
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recognition by ligase [13]. HMO1 facilitated formation of circles only with DNA longer
than 87 bp DNA (Figure 2.9), a lower efficiency that may correspond to either a reduced
bend angle or a short residence time of HMO1 on linear DNA.
Work by Lu et al. [30] reports that HMO1 introduces negative supercoils into
relaxed plasmid DNA, and that at high concentrations, HMO1 inhibits the unwinding
reaction. We did not find evidence that HMO1 has the capability to introduce supercoils
into relaxed plasmid DNA (Figure 2.10). In our work, we used recombinant HMO1,
while Lu et al. purified HMO1 from yeast on the basis of its association with a DNA
helicase activity, potentially resulting in isolation of posttranslationally modified protein
[30]. SRY, which is a modestly sequence specific HMGB protein, also failed to supercoil
relaxed DNA in the presence of topoisomerase I [45]. At position 37 of helix II where
intercalating hydrophobic residues are located for non-sequence specific HMGB proteins,
SRY has asparagine (Figure 2.1). Since the HMO1 box B and SRY both lack a
hydrophobic residue at position 37, this may correlate with their intrinsic inability to
supercoil relaxed DNA.
DNA minicircles most likely resemble possible distorted DNA targets, including
features of chromatin structure, DNA topology during recombination, or bends
introduced during transcription initiation. For HMO1, a much higher mass excess of
plasmid DNA was required to compete for binding compared to complexes involving
linear DNA (Figure 2.8). Presumably, the complex formed with the minicircle is less
dynamic compared to complexes involving linear DNA. This increased residence time is
probably a consequence of an optimized fit between the minicircle and HMO1. The more
stable association of HMO1 with constrained DNA is consistent with its role in
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maintaining the integrity of chromatin and in assembly of the rRNA preinitiation
complex [30, 32].
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CHAPTER 3
A ROLE FOR THE SACCHAROMYCES CEREVISIAE HIGH MOBILITY
GROUP BOX PROTEIN HMO1 BEYOND DNA BINDING
Introduction
High-Mobility-Group (HMG) proteins are a family of ubiquitous proteins that
constitute a significant fraction of non-histone nuclear proteins and are grouped into three
subfamilies, HMGA, HMGB, and HMGN [1-7]. These proteins are united by a common
theme in that they bind DNA or nucleosomes, altering the local conformation, therefore
increasing their accessibility and plasticity. Consequently, this facilitates and enhances
various DNA-dependent activities such as transcription, replication, recombination and
DNA repair (reviewed in [3, 6]). These three subfamilies have a unique protein signature
and a characteristic functional motif, such as the HMG-box in HMGBs, the AT-hook in
HMGAs, and the nucleosomal binding domain in HMGNs [2, 3, 6, 7].
HMGB proteins contain one or more homologous repeats of the ~80-amino acid
sequence HMG box. They bind to DNA in the minor groove and bend DNA ~90°
towards the major groove. HMGB proteins are classified into two families based on the
abundance, function and DNA specificity of the HMG box [1, 3, 6, 8]. The moderately
sequence specific family are transcription factors that usually contain a single HMG box,
for example transcription factors such as sex-determining factor SRY and lymphoid
enhancer factor LEF-1 [9, 10]. The non-sequence specific family binds DNA without
sequence preference but instead structural preference. They are represented by the socalled architectural factors HMGB1/2, ubiquitous proteins in vertebrates, and the
Saccharomyces cerevisiae non-histone chromosomal protein 6A and 6B (NHP6A/B)
[11].
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A recent global analysis of protein expression in yeast showed HMGB proteins
NHP6A/B and HMO1/2 to be present in the nucleus at moderately abundant levels [12].
NHP6A contains only one HMG box, which is 45% identical to rat HMGB1 box B and
80% identical to NHP6B [13]. NHP6B is a functional paralog of NHP6A, and their
biological function was determined using gene deletion experiments; a phenotype is only
observed in the nhp6a/b double knockout. Double mutant (nhp6∆∆) cells exhibit 50%
reduction in growth rate at 30°C and cannot grow at 37°C in the absence of osmotic
support [14]. NHP6 has multiple roles in transcription, including transcriptional initiation
and elongation by Pol II and transcription by Pol III [15, 16]. For example, it has been
shown that the nhp6∆∆ growth defect can be suppressed by a multicopy plasmid with
either SNR6 or BRF1 [15]; SNR6 encodes the U6 RNA required for mRNA splicing, and
it is suggested that a deficiency in SNR6 RNA contributes to the temperature-sensitive
growth defect seen in nhp6∆∆. BRF1 is the limiting component in TFIIIB, a factor
required for Pol III transcription [17]. It is therefore likely that overexpression of BRF1
increases SNR6 expression which in turn facilitates the growth of nhp6∆∆ at 37°C.
Overexpression of TATA-binding protein (TBP) also suppresses the temperaturesensitive growth defect of nhp6∆∆ [18]. TBP overexpression could suppress the nhp6∆∆
growth defect by affecting either Pol II or Pol III transcription because in addition to its
well-documented role in Pol II transcription, TBP is also a component of the RNA Pol III
initiation factor TFIIIB[16, 19]. It has also been demonstrated that NHP6 is required for
maximal transcription of the HO endonuclease gene [20, 21]. For its role in elongation,
NHP6 interacts genetically and biochemically with SPT16/POB3 [22, 23], the yeast
equivalent of FACT (FAcilitates Chromatin Transcription, which is an accessory factor
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present in HeLa cell nuclear extract) that promotes elongation through chromatin
templates [24]. NHP6 is required for SPT16/POB3 to bind to nucleosomes [23, 25].
HMO1 and HMO2 are ~25 kDa HMG-box proteins, identified by homologybased motif-prediction programs as having only a single HMG-box, in a position
corresponding to box B of mammalian HMGB. However, HMO1 also contains an Nterminal box A domain with weak similarity to consensus HMG-box domains, which was
recently shown to participate in DNA binding [26], and a long run of basic residues in the
C-terminus, not found in any other HMGB proteins. Strains bearing HMO1 or HMO2
mutant alleles are viable, although HMO1 mutant strains have growth defects,
compromised plasmid maintenance and nuclease sensitive chromatin, suggesting that
HMO1 may play a role in stability of the chromatin structure. A double knock-out of
HMO1 HMO2 could not be rescued by addition of an osmotic stabilizer to the medium at
37°C as with nhp6∆∆, indicating that the mutant was not defective in osmotic tolerance
[27]. These authors also did not find any apparent synthetic phenotype of a triple mutant
nhp6a, nhp6b, hmo1suggesting that there is no functional overlap of these proteins in the
cells. In vivo, the HMO1 C-terminus is dispensible for function whereas HMG Box B is
essential [27]. As the basic C-terminus is predicted to harbor the nuclear localization
signal, an important implication of this observation is that the growth phenotype
characteristic of the hmo1 knockout may be reversed by HMO1 mutant protein that is
confined to the cytoplasm. Immuno-localization experiments have shown that full length
HMO1 is present both in the nucleus and cytoplasm [27].
Here we report generation of various combinations of NHP6, HMO1 and HMO2
mutant strains. It is evident from the data obtained that certain HMO2 mutant strains have
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a slower growth phenotype, contrary to the previous report [27]. Using fusions to green
fluorescent protein (GFP), we show that a HMO1 mutant deleted for the C-terminal tail
(HMO1-boxAB) was localized to the cytoplasm. In contrast, HMO1-GFP was distributed
both in the nucleus and the cytoplasm, as previously reported [27, 28]. As also reported
by Lu et al. [27], we find that growth rates of yeast strains expressing HMO1-GFP and
HMO1-boxAB-GFP were the same. This is indicative of essential and unique functions
of HMO1 protein in the cytoplasm, and not in the nucleus.
Experimental Procedures
Strains, gene disruption and expression
All the original strains used are listed in Table 3.1A and some of the generated
strains are listed in Table 3.1B. Standard genetic methods were used for strain
construction and gene disruption. Prototroph selection markers TRP1 and URA3 were
amplified from pRS424 and pRS426 plasmids, previously constructed and published by
Christianson et al. [29]. The of primers used for HMO1 and HMO2 gene disruptions are
listed in Table 3.2A. To amplify the selection marker with homologous sequence (~80
nucleotides) upstream and downstream of HMO1 for gene disruption, HMO1F and
HMO1R were used. For HMO2 gene disruption, HMO2F and HMO2R primers were
used. Ten µg of PCR product was used to transform DDY3 haploid yeast cells selecting
for tryptophan or uracil prototrophy. Transformants were assayed by genomic PCR with
one primer specific for chromosomal sequence upstream of the HMO1 or HMO2 open
reading frames and the second primer (universal) specific for the integrated selection
marker, to determine whether the selection marker had integrated at the appropriate locus
(Figure 3.1). The primer used to amplify the upstream region of HMO1 was HMO1UF
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Table 3.1 Yeast strains used in the experiments. A. Original strains. B. Yeast strains
generated in this work.

A
Strain

Genotype

DDY3

MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 GAL can1-100

DDY587

MATα ade2 can1 his3 leu2 LYS2 trp1 ura3 nhp6a:URA3 nhp6b:HIS3

DDY591

MATα ade2 can1 his3 leu2 LYS2 trp1 ura3 nhp6a:KanMX nhp6b:ADE2

B
Strain

Genotype

DDY1295

MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo1∆::TRP1

DDY1301

MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo2::URA3

DDY1329

MATα ADE2 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1
nhp6b:HIS3

DDY1333

MATa ADE2 his3-11 leu2-3,112 lys2∆ trp1-1 ura3-1 hmo2::URA3
nhp6a:KanMX

DDY1385

MATa ade2 can1 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1
hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3

DDY1386

MATa ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1
hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3

DDY1387

MATa ADE2 his3 leu2 LYS2 trp1 ura3 hmo1∆::TRP1
hmo2∆::URA3 nhp6a:KanMX nhp6b:HIS3

DDY1429

MATα ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1
hmo2∆::URA3

DDY1430

MATa ADE2 his3 leu2 lys2∆ trp1 ura3 hmo1∆::TRP1
hmo2∆::URA3
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Table 3.1 List of primers used. A. Primers used for to disrupt HMO1 and HMO2 genes
in the original DDY3 strain. B. Primers used for generation of GFP-tagged HMO1 and
HMO1-boxAB protein. Nucleotide sequence in upper case is the sequence homology to
the desired chromosomal insertion site and the lower case is the sequence homology to
the vector pFA6a-GFP.
A

PCR primers used for gene disruption

Primer name

Nucleotide sequence (5′

3′)

HMO1F

CCCAGCGGGCCCTCAGGGCTGGTCTACTGCCTTATACTCTAGGATGTACATCC
TACCACACACAACAAGCCTGTCACACCGCAGATTGTACTGAGAGTGC

HMO1R

TATATTTTATTCCTTTTTTTATTATTATATTTATTTTAGAAAGACAGTAGAGT
AATAGTAACGAGTTTGTCCGTCCATCACTCCTTACGCATCTGTGCGG

HMO2F

GCACATATATATTAAATCGTTCTAGGGGCTAGAATTGGATGAGAAGCAGCCAGG
ATATAGGTAATAGTAACACATAAGAAGCAGATTGTACTGAGAGTGC

HMO2R

TTGAACAATTTCTGGATAAAGCGCCTAGAACGTCTTACGATATCTTCAAAGAAA
ATAGAAAAAAATGGAATTTTTAATTTCTCCTTACGCATCTGTGCGG

HMO1UF ACCCGACTCGATTATCTACC
HMO2UF GTGCTAAGAAATCTTGTGCACG
UU

GCACTCTCAGTACAATCTGC

HMO1DF GGATTATGAGTTTCCTGAACAC
HMO2DF TGGTAATAAAAGCCACGTCTAG
DD

CCGCACAGATGCGTAAGGAG

B
Primer name

PCR primers used for generation of GFP-tagged protein
Nucleotide sequence (5′

3′)

HMO1-GFPF GAAGAAGGATAAGAAGAAGGACAAATCCAACTCTTCTATTggtcgacggatccccggg
HMO1-GFPR AGAAAGACAGTAGAGTAATAFTAACGAGTTTGTCCGTCCAtcgatgaattcgagctcgtt
boxAB-GFPF

CCAACTCATGCGCCGGTTCCAATTCCTTTCAGTTTACAGCACGCCggtcgacggatc
cccgggtt
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PCR product

Selection marker

Chromosomal
HMO1 locus

HMO1/2

Selection marker
Integrated in the
chromosome

Integrated marker

Figure 3.1 Strategy for generation of HMO1 or HMO2 knockout. DDY 3 cells were
transformed with PCR products containing the selectable marker gene and sequence
homologous to the upstream and down stream of gene of interest (black region on the PCR
product), HMO1 or HMO2. Through homologous recombination, HMO1 or HMO2 was
knocked out and replaced with the integrated selectable marker. Transformants were
assayed by genomic PCR with one primer specific for chromosomal sequence upstream of
the HMO1 or HMO2 open reading frames and the second primer (universal) specific for the
integrated selection marker, to determine whether the selection marker had integrated at the
appropriate locus. The position and direction of the primers is shown as arrows.
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and HMO2 was HMO2UF. The upstream universal reverse primer was UU. The
sequence of the primer used to amplify the downstream region for HMO1 was HMO1DF
and HMO2 was HMO2DF and the downstream universal reverse primer sequence DD
(Table 3.2A). The hmo1∆ (DDY1295) and hmo2∆ (DDY1301) mutant strains were
generated. DDY1329 was generated by mating DDY587 with DDY1295 and selecting
for prototrophy tryptophan (HMO1) and histidine 3 (NHP6B). DDY1333 was generated
by mating DDY591 with DDY1301 and selecting for uracil prototrophy (HMO2) and
antibiotic Kanamycin antibiotic resistance (NHP6A). DDY1333 and DDY1329 cells
were mated and grown in sporulation media for tetrad dissection.
Construction and analysis of GFP-tagged HMO1 and HMO1-boxAB
HMO1 was C-terminally tagged with GFP at its chromosomal location through
oligonucleotide-directed homologous recombination (Figure 3.2). To generate HMO1GFP, a pair of oligonucleotides were generated that had homology to the C-terminus of
HMO1 (upper case in the primer sequence), which was the desired chromosomal
insertion site at the 5' end of each primer and homology to vector pFA6a-GFP (F64L,
S65T, R80Q, V163A)-His3MX6 (lower case in the primer sequence) containing the GFP
tag and Histidine 3 as the auxotrophic marker at the 3' end. Vector pFA6a-GFP was
kindly provided by Dr. Mark Longtine [30]. To generate HMO1-GFP, the forward primer
used was HMO1-GFPF and the reverse primer used was HMO1-GFPR. To generate
HMO1-boxAB, the forward primer was designed such that the sequence homology of the
oligonucleotides deleted 36 amino acids from the C-terminus. The forward primer used
was boxAB-GFPF and the same reverse primer as for HMO1 was used. The PCR
products were used to transform DDY3 cells. Cells were grown in YMD-His media
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PCR product

Chromosome
HMO1/2

Fusion protein

HIS3MX6

GFP
Homologous
recombination
HMO1/2 ORF

HMO1/2 Protein

HIS3MX6 protein

GFP

Figure 3.2 Strategy for generation of HMO1-GFP or HMO1-boxAB-GFP fusion
protein. DDY cells were transformed with PCR products containing the GFP tag and
HIS3 auxotrophic marker gene. The GFP was inserted at the C terminus of HMO1 or
HMO1-boxAB through homologous recombination, yielding a C-terminally GFP-tagged
protein.
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(minimal media lacking histidine), to select for cells that had integrated the auxotrophic
selection marker gene into their chromosome. Transformants were assayed by genomic
PCR with one primer specific for the GFP tag and a second specific for the
HMO1/HMO1-boxAB open reading frame, to determine whether the cassette had
integrated at the appropriate locus. The PCR product obtained was sequenced to ensure
that the gene cassette had been integrated at the appropriate locus in-frame. The cells
were then analyzed by multiple wavelength fluorescence and visible light microscopy
with digital imaging-capable using at x40 magnification.
Results
Characterization of mutant phenotypes
DDY1333 (hmo2, nhp6a) was mated with DDY1329 (hmo1, nhp6b), sporulated
and subjected to tetrad analysis (Figure 3.3). Four viable spores were obtained showing
that none of the four genes are essential for viability as previously shown [27]. Colonies
were visually analyzed, looking at the sizes and light intensity. Table 3.3 shows the genes
that were inactivated from each spore in Figure 3.3. Although the quadruple knockout
was viable, it gave rise to the smallest colonies (A2, data not shown). Triple knockouts
C1 (hmo1, hmo2, nhp6a) and A5 (hmo1, nhp6a, nhp6b) gave the second smallest
colonies after the quadruple knockout. The ∆nhp6a, ∆nhp6b and ∆hmo2 single knockouts
did not show any phenotype (compare B2, C2, D3, A4, B5, C5 to the wildtype A1).
Interestingly, when the HMO2 gene was deleted in the context of an HMO1 knockout,
slightly smaller colonies with lower light intensity compared to ∆hmo1 (D2, C3) were
obtained (A3, D4, A6). It is also noteworthy to compare colony C1 to B4; the slightly
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A
B
C
D

Figure 3.3 Phenotype of various mutants from a tetrad dissection. DDY1333 was
mated with DDY1329, sporulated and subjected to tetrad analysis. Spores were
germinated and grown on YPD plate for 3 days at 30°C. The genotype of each spore was
scored using the standard method, by replica plating to minimal media lacking the
nutrient corresponding to each marker gene (or containing G418 for the KanMX marker)
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TABLE 3.3 Tetrad analysis
Spore location in Figure 3.2

Genes Knocked out

A1
B1
C1
D1

None
NHP6A, NHP6B, HMO2
NHP6A, HMO1, HMO2
HMO1, HMO2

A2
B2
C2
D2

NHP6A, NHP6B, HMO1, HMO2
NHP6A
NHP6B, HMO2
HMO1

A3
B3
C3
D3

HMO1, HMO2
NHP6A, NHP6B, HMO2
HMO1
NHP6A, HMO2

A4
B4
C4
D4

NHP6B, HMO2
NHP6A, HMO1
NHP6A, NHP6B
HMO1, HMO2

A5
B5
C5
D5

NHP6A, NHP6B, HMO1
HMO2
NHP6A
NHP6B, HMO1, HMO2

A6
B6
C6
D6

HMO1, HMO2
NHP6A
HMO1, HMO2, NHP6B
NHP6A, NHP6B
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larger B4 colony is ∆nhp6a ∆hmo1, while C1 is ∆nhp6a ∆hmo1 ∆hmo2, indicating that
the difference in size is due to a ∆hmo2 phenotype. ∆hmo1 ∆hmo2 (A3, D4, A6) have
smaller colonies with less light intensity compared to ∆∆nhp6 (C4, D6) whereas ∆hmo1
(D2, C3) compares to ∆∆nhp6. While the previously reported absence of a growth
phenotype upon inactivation of hmo2 was inferred based on comparison to wild type
cells, our data show that a growth phenotype may be detected in an hmo1 mutant
background.
Localization of HMO1-GFP and HMO1-boxAB-GFP in yeast cells
HMO1 has previously been shown to be both a nuclear and cytoplasmic protein
[27, 31]. In these experiments, we confirm the localization of HMO1-GFP to both the
nucleus and the cytoplasm. However, HMO1-boxAB-GFP was localized only in the
cytoplasm (Figure 3.4). Lu et al. [27] showed that a plasmid expressing the full length
HMO1 or HMO1-boxAB complemented the hmo1 mutant phenotype, but a plasmid
expressing HMO1 deleted for 30 amino acids of box B did not. This implies that the
ability of HMO1 to rescue the hmo1 mutant phenotype is in the cytoplasm and not in the
nucleus. This also confirms that the Nuclear Localization Signal (NLS) of HMO1 is
located at the C-terminus as predicted by the NLS prediction program on the
www.expasy.org website.
Discussion
Growth phenotype
HMO1 was first identified by its co-purification with a DNA helicase.
Genetically, HMO1 was shown to be required for normal growth, plasmid maintenance
and for regulating susceptibility of yeast chromatin to nuclease [27]. These authors
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A

B

Figure 3.4 In vivo localization of HMO1-GFP and HMO1-boxAB-GFP proteins. A.
HMO1-GFP is distributed both in the nucleus and the cytoplasm. The image on the right
panel is the face contrast shot of the same cell. B. HMO1-boxAB-GFP is distributed in
the cytoplasm. The image on the right panel is the face contrast shot of the same cell.
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proposed that HMO1 binds to the small linker DNA of yeast, stabilizing a higher-order
chromatin structure which is important for normal gene expression and/or DNA
replication. Dolinski and Heitmain [31] showed that HMO1 interacts genetically and
physically with FKBP12 Prolyl Isomerase. HMO1 has also recently been identified as a
genuine RNA polymerase I, factor acting synergistically with Rpa49 (DNA-directed
RNA polymerase I 49 kDa polypeptide, which is a non-essential but conserved subunit of
RNA polymerase I corresponding to the animal RNA polymerase factor PAF53) during
rDNA transcription [32]. In this study, we have shown that the unique functions of
HMO1 are confined to the cytoplasm. Lu et al. [27] noted that HMO1 mutants were
viable most likely because other proteins performed the essential functions of HMO1,
although they might lack the abundance or binding properties to optimally replace loss of
HMO1. In fact, a recent global analysis of protein expression in yeast revealed HMO1 as
the most abundant HMGB protein in yeast [33]. By virtue of it abundance, HMO1 can
likely protect the chromatin from nuclease digestion as observed for hmo1∆ [27]. These
authors also showed that NHP6 had non-overlapping functions with HMO1 in the cell.
Therefore, it is most likely that HMO2 would replace the function of HMO1 in the cell.
In comparison to other HMGB proteins, both HMO proteins have a divergent A box
where conserved and charged residues have been replaced by unrelated residues. The B
box however, is highly conserved showing higher identity with the consensus. HMO2
lacks the unique highly basic C-terminal tail found in HMO1. Interestingly, we have
observed a slight slow growth HMO2 phenotype that is only evident in hmo1 hmo2
mutant strains (Figure 3.2 , Table 3.2). ∆hmo2 alone does not show any apparent
phenotype, most likely because the more abundantly expressed HMO1 takes over the
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function of HMO2. In addition, the lack of a synthetic phenotype between NHP6 and
HMO2 suggests that they have non-overlapping functions in the cell as well (Figure 3.2,
compare spores B3 to D6), further confirming that HMO1 is the likely protein that
replaces the function of HMO2 in ∆hmo2 cells, and HMO2 replaces some of the
functions of HMO1 in ∆hmo1 cells. Overexpression of HMO2 in ∆hmo1 strains would
address this hypothesis.
Cellular localization
The C-terminus of HMO1 is dispensible for function in vivo [27]. These authors
showed that a plasmid expressing the full length HMO1 or HMO1-boxAB complemented
the mutant phenotype. Interestingly, we have localized HMO1-boxAB to the cytoplasm
(Figure 3.4). This is a clear indication that the essential and unique functions of HMO1
are located in the cytoplasm and not in the nucleus. This data is supported by the fact that
HMO1 genetically and physically interacts with cytoplasmically expressed FKBP12
Prolyl Isomerase, a product of the FPR1 gene, which when mutated has been shown to
be synthetic lethal with ∆hmo1[31]. We have previously shown that HMO1 has distinct
DNA binding and bending properties from other HMGB proteins, consistent with its
unique role in vivo [26]. Although HMO1 was speculated to play a role in organizing
target structures for yeast RNA polymerase I-dependent transcription, direct interaction
between HMO1 and Rpa49 or RNA polymerase I was not detected [32]. S. cerevisiae
SPT16/CDC68 and POB3 (Polymerase one-binding) form a heterodimer, localizes to the
nucleus and have been shown to affect DNA replication and transcription globally [23,
33, 34, 35]. STP16 and POB3 show strong genetic interactions with NHP6 but only
minor interactions with HMO1 or HMO2 [23, 27].

72

Lu et al.[27] described HMO1 as a likely homolog of HMGB1/2. HMGB1 has
been considered as a ubiquitous nuclear protein with an architectural function, but it had
also been described to be present in the cytoplasm [36]. Today, extranuclear and
extracellular functions of HMGB1 have just started to come into focus. It participates in
developmental and differentiation processes, triggers and modulates many of the
inflammatory cascades in the body, and may even be involved in the metastatic invasion
programme of cancer cells (reviewed in [37]). Similarly, our data indicate that HMO1 has
extracellular functions which may or may not be similar to those of HMGB1. Notably,
signaling by TOR (Target of Rapamycin) kinases is central to environmental stress
responses in yeast. Suppression of TOR signaling, for example through inhibition of TOR
kinases by interaction with FKBP12-rapamycin, leads to cell cycle arrest (reviewed in
[38]). The reported interaction between HMO1 and FKBP12 suggest a possible role for
HMO1 in such signaling pathways. Studies to characterize the extranuclear function of
HMO1 will further expand signaling roles of HMGB proteins beyond HMGB1, which
thus far is the only HMGB protein that has been shown to have signaling capabilities,
expanding the importance of HMGB proteins across organisms.
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CHAPTER 4
PHOSPHORYLATION OF SACCHAROMYCES CEREVISIAE HIGH MOBILITY
GROUP BOX PROTEIN HMO1 BY CASEIN KINASE II AND THE ROLE OF
THE C-TERMINAL DOMAIN IN DNA BINDING AND PROTEIN STABILITY
Introduction
High-Mobility-Group (HMG) proteins are relatively abundant non-histone
nuclear proteins with one or more homologous DNA binding domains, the HMG box,
each of ~80-amino acid residues. HMGB proteins are classified into two families based
on their abundance, function and DNA specificity [1-5]. Some are transcription factors
that bind DNA with sequence-specificity; they usually contain a single HMG box and are
expressed in a few cell types [6]. They are exemplified by sex-determining factor SRY
and lymphoid enhancer factor LEF-1 [7, 8]. The non-sequence-specific family binds
DNA without sequence preference but instead structural preference. They are typified by
HMGB1/2, ubiquitous, vertebrate, non-sequence specific HMGB proteins, and
Saccharomyces cerevisiae non-histone chromosomal proteins 6A and 6B (NHP6A/B) [3,
9, 10]. The role of HMGB1 in regulation of transcription, either by remodeling chromatin
and nucleosome structure or through direct interaction with transcription factors such as
Hox, steroid hormone receptors, p53, NF- B, and TBP is well documented (reviewed in
[11]). The HMGB1 knockout mouse dies shortly after birth due to hypoglycemia from a
defect in the transcriptional function of the glucocorticoid receptor [12]. Outside the cell,
HMGB1 functions as a cytokine [13, 14] and is a ligand for a membrane receptor, RAGE
[15, 16].
The structures of HMG boxes both from the non-sequence and the sequence
specific subfamilies have been determined in the presence and/or absence of DNA,

76

revealing a general global fold, characterized by a 3-dimensional, L-shaped structure with
three α-helices (reviewed in [11, 12]). The HMG box binds to the DNA minor grove by
partial intercalation of one or two conserved hydrophobic residues, causing the DNA to
be highly distorted, resulting in a sharp bend and helical underwinding [8, 17, 18, 19, 20].
Posttranslational modification of HMGB proteins has been reported, but the
functional significance of these modifications, except for the acetylation, is unknown
[21]. Phosphorylation of HMG proteins appears to be a common posttranslational
modification that is found in evolutionarily distant organisms [22]. For example, pulselabeling studies on phosphorylation of the Chironomus HMGB1a and HMGB1b proteins
showed that these proteins are phosphorylated by protein kinase C [23] and by Casein
kinase II (CKII) [22]. Broccoli (Brassica oleracea) HMGB protein was found to copurify with CKII with very high affinity and was efficiently phosphorylated even in the
presence of an excess of exogenous substrates [24]. CKIIα phosphorylates the acidic Cterminal domain of the HMGB1 and HMGB2/3 proteins [25]. HMG phosphorylation
appears to alter the conformation, stability, and DNA binding properties of these proteins
and is therefore essential for their function. For example, DNA supercoiling properties of
HMGB1 were shown to be modified by phosphorylation [25, 26].
Basic extensions found either C- or N-terminal to the HMG box are known to
increase the bending capacity and DNA-binding affinity of the HMG box. For example,
the 16 basic amino acids found at the N-terminus of the NHP6A HMG box is required for
stable complex formation on both linear DNA and DNA minicircles [20]. Basic Cterminal extensions stabilize binding of HMG-D and LEF-1 by binding in the major
groove opposite the distorted minor grove [8, 27].
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The HMGB1/2 acidic tail has been shown to lower the affinity of the HMG boxes
for most DNA substrates, such as linear DNA, supercoiled DNA and 4-way junction
(reviewed in [28]). Interestingly, the tail is not important for structure-selective DNAbinding of the HMG boxes to DNA minicircles since it has little effect on the affinity for
DNA minicircles compared to other DNA substrates in vitro [29]. However, it was not
established whether this is a consequence of interaction of the tail with the HMG box(es)
or the basic extension region or simply charge repulsion. Thomsen et al. [30] showed that
interactions of the basic N-terminal and acidic C-terminal domains of the maize HMGB1
may contribute to regulation of the DNA interactions of the protein. A similar
phenomenon was also observed for Arabidopsis HMGB1 and HMGB4 [30]. This led the
authors to argue that the interaction of the variable terminal domains of the different plant
HMGB proteins could serve as a molecular mechanism involved in the fine tuning of the
functional properties of these architectural proteins, depending on the structural
requirements of specific nucleoprotein complexes.
S. cerevisiae contains several HMG-box proteins. For example, HMO1 is
identified by homology-based motif-prediction programs as having only a single HMGbox, in a position corresponding to box B of mammalian HMGB1. However, HMO1 also
contains an N-terminal box A domain with weak similarity to consensus HMG-box
domains. HMO1 and HMO2 genes are non-essential, but deletion of HMO1 gene confers
growth defects, impaired plasmid maintenance and nuclease sensitive chromatin [31].
HMO1 has also been shown to interact with FKBP12, an abundant protein that interacts
with a number of cellular proteins, including the target of Rapamycin (TOR) kinases that,
for example, regulate rDNA transcription [32, 33]. A recent study includes HMO1
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directly in the rRNA transcription apparatus, where it was proposed to function in a
similar capacity as the Upstream Binding Factor (UBF), an auxiliary factor in the
mammalian and amphibian RNA Polymerase I transcription systems; UBF has six HMG
domains [34].
We have previously shown that the divergent HMO1 box A domain participates
in DNA binding, and that it contributes modest structure-specific DNA binding to
HMO1, while box B confers most of the DNA binding affinity [35]. In this study we
show that HMO1 and HMO1 deleted of its C-terminal tail (HMO1-boxAB) get
phosphorylated by CKII, yielding proteins with reduced affinity for DNA. These data
suggest that HMO1 can be regulated by posttranslational modification. We have also
analyzed the role of the HMO1 basic C-terminal tail in DNA binding. Circular Dichroism
(CD) Spectroscopy measurements of protein melting temperatures revealed that HMO1boxAB has a higher melting temperature than the wild type, suggesting that the Cterminal domain destabilizes the protein.
Experimental Procedures
Cloning and Purification of Proteins
The gene encoding HMO1 was amplified from yeast genomic DNA and
subcloned into pET28b for expression with an N-terminal His6-tag. HMO1-boxA was
generated as previously described [35]. To generate HMO1-boxAB, PCR-based sitedirected mutagenesis was used to replace Ala210 with a stop codon. The sequence of the
primers used are available upon request. Recombinant plasmids were used to transform
E. coli Rosetta Blue strain (Novagen). Proteins were purified as previously described
[35].
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Circular Dichroism Spectroscopy
CD spectra were recorded on an AVIV Model 202 CD spectrophotometer using a
1 cm pathlength sample cell. Wavelength scans from 200 nm to 300 nm were performed
in triplicate, and data points were averaged and smoothed using standard methods. The
wavelength scan for His6-tagged HMO1 was recorded at 25ºC, with a protein
concentration of 0.025 mg/ml in 2.5 mM NaxHyPO4, pH 7.0, 0.5% glycerol, 10 mM
NaCl. The wavelength scan for His6-tagged HMO1-BoxA was recorded at 4ºC, using a
protein concentration of 0.05 mg/ml in 1 mM Tris, pH 7.0, 0.03% Tween 20, 10%
glycerol, 2.8 mM KCl. For measurement of thermal stability, protein was diluted to 0.05
mg/ml in CD buffer (20 mM potassium phosphate (pH 7), 8 µM EDTA, 0.2% glycerol, 3
mM KCl), and measurements were made using a quartz cuvette with a 1-cm path length.
Ellipticity readings from 300 to 200 nm (1-nm steps) were taken over the temperature
range 19–70 °C, with steps of 3 °C (19–37 and 61–70 °C) or 1.5 °C (37–61 °C). Each
sample also underwent a reverse scan from 67 to 19 °C. Three minutes were allowed for
thermal equilibration after each step. Wavelength scans from 300 to 200 nm were
performed at 19 and 70 °C to verify the native and denatured states of the protein,
respectively. CD measurements of protein melting were performed in triplicate and
corrected for buffer contributions to the signal. Calculation of the Tm of the proteins was
made based on ellipticity measurements from 230 to 220 nm. Temperature-dependent
ellipticity values were plotted at each wavelength and fit to a two-state model for protein
unfolding [36]. The Tm is reported as the average ± S.D.
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Electrophoretic Mobility Shift Assays (EMSA) with 26 bp duplex DNA and 4-way
junction DNA
Four-way junctions were constructed as previously described; the sequence of
individual strands are as described [35, 37]. Briefly, the 4-way junction was prepared by
annealing the four strands, followed by purification of the junction on native
polyacrylamide gels. To ensure that all oligonucleotides were present, aliquots of the
purified junction were run on denaturing gels. EMSA was performed by incubating
reactions at room temperature in 10 µl reaction buffer containing 5 fmol DNA and
varying amounts of protein. Samples were resolved on prerun 7% (w/v) native
polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE (50 mM
Tris-borate, 1 mM EDTA) running buffer. Complexes were visualized by
phosphorimaging. Experiments were done at least in duplicate, and values are reported as
the mean ± standard deviation. For calculating fractional complex formation, the region
on the gel from the slowest migrating complex to the free DNA was considered as
complex and the binding isotherms for protein binding were fitted as described [35].
Ligase-Mediated Circularization
Ligation substrates were prepared by digestion of pET5a with BspHI to generate
a 105 bp fragment. DNA was 5'-end labeled with T4 polynucleotide kinase and ( -31P)
ATP. Reactions were initiated by addition of 20 units of T4 DNA ligase to a final volume
of 100 µl reaction buffer (20 mM Tris-HCl pH 8, 50 mM NaCl, 10 mM MgCl2, 0.1 mM
Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing 1200 fmol DNA, with or without the
protein. Time points were taken at intervals over 30 minutes. For each time point, 8 µl of
the reaction mixture was quenched by addition of 5 µl stop buffer (75 mM EDTA, 15%
glycerol, 0.1% bromophenol blue (BPB), 0.1% xylene cyanol, 6 µg/µl proteinase K).
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Samples were heated at 55°C for 15 minutes and resolved on prerun 7% (w/v) native
polyacrylamide gels (39:1 acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE.
Quantitation was performed on a Molecular Dynamics Storm Phosphorimager using
software supplied by the manufacturer.
Protein phosphorylation
Proteins were phosphorylated using Casein Kinase II (CKII, New England
Biolabs) as per the manufactures recommendation. One µg of protein was incubated with
1 unit of Casein Kinase II (CKII) in 1X CKII buffer (20 mM Tris-HCl pH 7.5, 50 mM
KCl, 10 mM MgCl2) supplemented with
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P-ATP with a final specific activity of 200

µCi/µmol in 10 µl final volume, and incubated at 30°C for one hour. Samples were run
on a 15% SDS-PAGE and quantification was performed on Molecular Dynamics Storm
Phosphorimager.
Protein cross-linking
Protein was incubated with 0.1% glutaraldehyde in 10 mM sodium phosphate (pH
7.0) at room temperature for 5 minutes. Samples were diluted 1:2 with SDS-sample
buffer, and analyzed by electrophoresis on 17% SDS-PAGE followed by Coomassie blue
staining.
Proteolytic digestion with Enterokinase and BNPS-skatole
For Enterokinase digestion, 2 µg protein was incubated at room temperature with
0.4 U Enterokinase (Novagen) in cleavage capture buffer (20 mM Tris pH 7.5, 50 mM
NaCl, 2 mM CaCl2), and aliquots taken after various times. The cross-linking reaction
was quenched by addition of 10 µl SDS-sample buffer and analyzed on 17% SDS-PAGE
gels. Proteins were detected by staining with Coomassie brilliant blue. For BPNS-skatole
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(2-(2-nitrophenyksulfenyl)-3-methyl-3-bromoindoleline) (Sigma) digestion, 2 µg of
protein were incubated with 40 µl BPNS-skatole solution (1 mg/ml in 80% acetic acid
and 01% phenol) in 35 µl acetic acid. After 36 h at room temperature, the samples were
lyophilized and analyzed as described above.
DNA Supercoiling
Reactions contained 0.2 µg relaxed closed circular pUC18 plasmid, prepared by
adding 2.5 units of Vaccinia topoisomerase I (Epicentre) to supercoiled pUC18 in
relaxation buffer (50 mM Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM
EDTA). After 1.5 h at 37°C, varying amounts of protein were added and the reactions
incubated for 1 h at 37°C. Reactions were quenched with 5 µl termination buffer (5X
TBE, 5% SDS, 15% sucrose, 0.1% BPB, 0.1% xylene cyanol, 2 µg/µl proteinase K) and
incubated for 1 h at 37°C. Samples were loaded on 1% 1X TBE agarose gels and
electrophoresed at 2 V/cm for 12 h in 1X TBE buffer.
Results
CD spectra and Melting temperature
Recombinant N-terminally His6-tagged HMO1, HMO1-boxAB and HMO1-boxA
were purified to apparent homogeneity, as judged by Coomassie Blue-staining of SDSPAGE gels (Figure 4.1, panel D). Based on CD spectra, we have previously shown that
HMO1 and HMO1-boxA have high α-helical content [35]. However, the CD spectrum of
HMO1-boxAB displayed only a single negative peak ellipticity at 222 nm (data not
shown). In fact, this peak was only achieved in the presence of high detergent (0.1%
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Figure 4.1 Thermal denaturation of HMO1 (A), HMO1-boxAB (B), HMO1-boxA (C).
Ellipticity measurements were recorded from 4 °C to 90 °C at wavelengths from 221-230
nm. D, SDS-PAGE showing purified His6-HMO1-boxA, His6-HMO1-boxAB and His6HMO1 in that order.
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Tween 20 compared to 0.03% for HMO1-boxA) and low protein concentrations (0.02
mg/ml compared to 0.05 mg/ml for HMO1-boxA, suggesting protein aggregation).
Thermal denaturations of HMO1 and HMO1-boxAB were biphasic, a process consistent
with a protein containing two distinct domains (Figure 4.1). HMO1 and HMO1-boxAB
had melting temperatures of 23.5 ± 0.4°C and 57.6 ± 0.8°C, and 48.2 ± 2.0°C and 71.7 ±
0.7°C respectively. However, HMO1-boxA melting occurred in a single transition at
52.2 ± 0.2°C, indicative of unfolding of a single domain (Figure 4.1). HMO1-boxAB had
a higher melting temperature than HMO1; in addition, HMO1-boxA had a relatively high
melting temperature compared to HMO1. This is an indication that the C-terminal tail
destabilizes the protein. However, it is also possible that with deletion of the C-terminal
tail, one domain became more stable (melting temperature increased from 23.5°C to
71.7°C) while the other domain became less stable (melting temperature decreased from
57.6°C to 48.2°C). Arguments to support the likelihood that the first transition is melting
of box A and the second transition is melting of box B is presented in the discussion.
HMO1-boxAB has lower affinity for DNA compared to the wild type protein
DNA binding was analyzed with Electrophoretic Mobility Shift Assays (EMSA).
We have previously shown that HMO1 has only modest preference for DNA with altered
conformations including the 4-way junction, which it binds with a half-maximal of 4.9 ±
1.5 nM (see figure 4 in [35]). HMO1-boxAB bound 4-way junction with a half-maximal
saturation of 27.9 ± 1.4 nM (Figure 4.2). The half-maximal values implicate participation
of C-terminal tail in DNA binding, directly or indirectly. Basic extension regions of
HMGB proteins have been shown to contribute to DNA binding properties [28, 30, 39].
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Figure 4.2 Binding of HMO1 (panel A) and HMO1boxAB (panel B) to 4-way junction
DNA. Reactions contain 5 fmol DNA, and protein concentrations are 0, 5, 7.5, 10, 25, 30,
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HMO1-boxAB does not bend DNA
Ligase-mediated circularization assays were performed where the efficiency with
which T4 DNA ligase mediates ring closure of DNA fragments that are shorter than the
persistence length is measured [20, 40]. The ability of HMO1-boxAB to enhance ligasemediated DNA circularization was qualitatively assessed with 105 duplex DNA. HMO1boxAB did not facilitate formation of minicircles, unlike HMO1 (Figure 4.3, [35]). It has
been shown that deletion of the basic N-terminus of NHP6A yields a protein with low
affinity for linear DNA that retains the ability to convert 40% of a 98 bp DNA fragment
into minicircles, compared to 70% for the wild type [20]. In contrast, HMO1-boxAB
bound linear duplex DNA with an affinity close to that of the wild type protein (data not
shown), but could not bend the DNA. This shows that HMO1 and NHP6A bind and bend
DNA differently. Conversely, incubation of DNA with C-terminal truncated HMGB1/2
yielded DNA minicircles at lower concentrations, probably reflecting the high affinity for
linear duplex DNA of these mutant proteins [28].
HMO1 and HMO1-boxAB are substrates for CKII
Using programs available for prediction of protein phosphorylation sites
(www.expasy.com), HMO1 was predicted to have many Ser/Thr residues that can be
phosphorylated by different kinases. CKII is a structurally and functionally conserved
enzyme that is widely distributed among eukaryotic organisms and previously shown to
phosphorylate HMGB1. S. cerevisiae has four essential genes that make up the protein
kinase CKII complex, CKA1, CHA2, CKB1 and CKB2. We therefore chose to use CKII
for analysis of HMO1. CKII is predicted to target six potential HMO1 phosphorylation
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HMO1

Exo III
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Monomer
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Time (min)
HMO1-boxAB

Exo III

Free DNA

Dimerized
DNA
Free DNA

Figure 4.3 Time-course ligation assay with 105 bp DNA. 100 fmol 105 bp linear DNA
was incubated with 1250 nM protein (HMO1 top panel and HMO1-boxAB lower panel)
up to 30 minutes. Time points were taken at 0, 0.5, 1, 2.5, 5, 10, 20, and 30 min.
Exonuclease III was added to reactions in the last lane at 30 min time-points. Circular
ligation products (the last lane top panel) were resistant to digestion by Exonuclease III.
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sites at positions, Ser11, Ser19, Ser33, Try54, Ser137 and Ser153. Equal amounts of
HMO1, HMO1-boxA and HMO1-boxAB were reacted with CKII and
phosphorylated proteins were resolved on SDS-PAGE gel, and
determined using phosphorimaging (Figure 4.4).

32

32

P-ATP. The

P incorporation was

HMO1 and HMO1-boxAB were

phosphorylated, but HMO1-boxA was not. This data suggests that Ser137 and/or Ser153
are the phosphorylation sites for HMO1 by CKII, as these sites are located in the box B
domain. CKII is a 130 kDA protein with α2β2 tetrameric structure. The 44 kDA α subunit
is catalytic and the 26 kDA β subunit is thought to have regulatory properties, but it also
gets autophosphorylated. HMO1-boxAB migrates at the same rate as the β subunit; hence
it was not possible to resolve its phosphorylation on this gel. EMSA was carried out to
compare binding to 4-way junction DNA by HMO1 and HMO1-boxAB before and after
phosphorylation. Phosphorylated proteins showed lower DNA binding affinity (Figure
4.4). To investigate if phosphorylation of HMO1 changed its DNA bending properties,
ligase-mediated circularization assays were performed with phosphorylated HMO1 (data
not shown). There was no discernable difference in minicircle formation between
phosphorylated and non-phosphorylated HMO1.
HMO1 forms oligomeric complex in solution
Based on the molecular mass of HMO1 eluting from a sizing column, Lu et al.
had predicted that HMO1 exists as an oligomeric complex in solution [31]. Cross-linking
reagents can provide the means for capturing protein:protein complexes by covalently
bonding them together as they interact. When HMO1 and HMO1-boxAB were incubated
with 0.1% glutaraldehyde, they formed oligomeric complexes, as judged by SDS-PAGE
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gel. However, HMO1-boxA formed oligomeric complexes, with dimers clearly forming
(Figure 4.5).
A

44 kDA α
subunit
Phosphorylated
HMO1

26 kDA β
subunit

1

2

B
P-HMO1-boxAB HMO1-boxAB

P-HMO1

HMO1

Complexes
DNA
1

2

3

4

5

6
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9
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12

13

Figure 4.4 (A) Phosphorylation of HMO1. Using 31P-ATP, HMO1 was phosphorylated
with CKII, resolved on SDS-PAGE and scanned on a PhosphorImager. Lane 1 shows
autophosphorylation of CKII. Lane 2 shows HMO1 phosphorylated. (B) DNA binding
by phosphorylated HMO1 and HMO1-boxAB. HMO1 and HMO1-boxAb were
phosphorylated and then used for EMSA with 4-way junction DNA. Lane 1 was the
control with no protein. Increasing concentration (10, 20 or 40 nM) of phosphorylated or
protein that has not been phosphorylated was used.
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monomer
1
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Figure 4.5 SDS-PAGE showing HMO1-boxA cross-linking. Protein was incubated
with 0.1% glutaraldehyde and time points taken at 2.5, 5 and 7.5 minutes, Lanes 2-4.
Lane 1 has no glutaraldehyde. Reactions were stopped by adding 10µl SDS-PAGE
sample buffer and loaded on a 17% gel.
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Protein cleavage analysis
Many proteins undergo significant conformational changes after binding to a
ligand. Such changes can be assessed by cleaving the protein at different locations using
peptide cleavage reagents. Using programs available for prediction of peptide cleavage
sites (www.expasy.com), HMO1 was predicted to have 2 Enterokinase cleavage sites
(Lys48, Lys84) and 2 BNPS-skatole [2-(2-nitrophenylsulfenyl)-3-methylindole] cleavage
sites (Trp149, Trp160). Enterokinase is a serine protease that recognizes the amino acid
sequence -Asp-Asp-Asp-Lys-|-X and activates its natural substrate trypsinogen and
releases trypsin by cleavage at the C-terminal end of this sequence. BNPS-skatole is a
mild oxidant and brominating reagent that leads to polypeptide cleavage on the Cterminal side of tryptophan residues. It was evident from appearance of fast migrating
protein fragments on SDS-PAGE gel, which corresponded to the cleaved protein
fragments of appropriate sizes, that HMO1 and HMO1-boxAB were cleaved by both
reagents as expected (Figure 4.6). However, addition of DNA to the reactions did not
change the cleavage pattern. This shows that the binding of HMO1 and HMO1-boxAB to
DNA substrate does not cause significant conformation change to alter the accessibility
of the amino acids cleaved by these reagents.
Discussion
Interdomain interactions in HMO1
Based on thermal melting of HMGB1, Ramstein et al. [41] proposed that HMGB1
box A and B behave as independent domains in a protein truncated of the acidic Cterminus (A-B), and that the C-terminus interacts with one of the two domains.
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Figure 4.6 Digestion of HMO1 and HMO1-boxAB with BNPS-skatole. The top panel
is a cartoon representation of possible protein fragments sizes after digestion of HMO1
and HMO1-boxAB with BNPS-skatole which cleaves at Trp149 and Trp160. The lower
panel shows protein digested with BNPS-skatole in the absence or presence of 4-way
junction DNA after electrophoresis on a 17% SDS-PAGE gel. Lanes 1 and 4 shows
undigested protein. Lanes 2 and 5 shows protein digest in the absence of DNA. Lane 3
and 6 show protein digested in the presence of DNA. Cleaved protein fragments are
identified at the right in the order of descending sizes as per the top panel, 1, 2, 3, 3b and
4b.
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They showed the thermal melting of box A and B to be identical with transition
temperatures of 43 ° C and 41° C, respectively, and the melting temperature of A-B had
nearly identical transitions of 40° C and 41° C. On the other hand, full length HMGB1
had biphasic transition values of 38° C and 55° C. The difference in the thermal melting
temperature between A-B and HMGB1 indicated that the C-terminus interacted with one
of the domains (as a result of increase of melting temperature from 41° C or 43°C to
55°C), stabilizing the protein. We have shown that HMO1 and HMO1-boxAB goes
though a biphasic thermal denaturation processes, indicative of two underlying melting
processes. HMO1-boxA has a theoretical pI of 4.08, 15 negatively charged residues and 4
positively charged residues, whereas HMO1-boxB has a theoretical pI of 10.07, a total of
12 negatively charged residues and 15 positively charged residues. The C-terminal tail
(the last 30 amino acids) has a theoretical pI of 10.07, 6 negatively charged residues and
14 positively charged residues. The high net positive charge of the C-terminus will
interact with the high net negative charge of box A. It is also likely that the net positive
charges in box B will interact with high net negative charges residues in box A. The
amount of net charge helps argue for a stronger interaction of C-terminal tail with box A
than with box B. Therefore, it is more likely that the larger change seen in melting
temperature due to the removal of the C-terminal tail in HMO1-boxAB is due to severed
interaction with box A. It is also likely that with the removal of the C-terminal tail, the
interaction of box A and box B changes. It has been shown that removal of the basic
region of HMGB protein increases the melting temperature of the protein [30]; an
indication that interaction of the basic region with the protein domain lowers the melting
temperature (destabilizes the protein). HMO1-boxA melts at 52.2 ± 0.2°C while HMO1-
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boxAB melts at 48.2 ± 2.0°C and 71.7 ± 0.7°C. Interaction of box B with box A in
HMO1-boxAB is likely to lower the melting temperature in box A compared to an intact
box A in HMO1-boxA. This would then imply that the first transition seen in HMO1boxAB represents melting of box A. Therefore, in full length HMO1, interaction of the
C-terminal tail and box B with box A destabilizes box A, and in HMO1-boxAB,
interaction of box B with box A destabilizes box A. We can therefore conclude that the
second transitions seen both in HMO1 and HMO1-boxAB represent unfolding of box B.
It is also unlikely that HMO1 box A and box B operate as independent domains since
both domains interact with the C-terminal tail, unlike HMGB1 [41].
DNA binding and bending properties of HMO1-boxAB
Basic extensions found either C- or N-terminal to the HMG box are known to
have a positive effect on bending capacity and DNA-binding affinity of the HMG box.
This region stimulates binding to linear DNA and 4-way junctions, DNA supercoiling
and circularization of short DNA fragments (reviewed in [28, 39]). For example in yeast,
the basic N-terminus of the NHP6A HMG box is required for stable complex formation
on both linear DNA and DNA minicircles. At high concentrations, mutants lacking the
N-terminus are able to promote minicircle formation and Hin invertasome assembly, but
they are unable to form stable complexes with DNA, co-activate transcription, and
complement the growth defect of ∆nhp6a/b mutants [20]. Basic C-terminal extensions
stabilize binding of HMG-D and LEF-1 by binding in the major groove opposite the
distorted minor grove [8, 27]. Severe negative effect are seen when the basic N-terminal
domains of maize and rice HMGB1 are deleted [42, 43]. In this study, we show that
deletion of the basic C-terminus of HMO1 has a negative effect on DNA affinity. It is
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likely that the basic C-terminus contributes to DNA affinity of this protein by directly
interacting with the DNA since it is highly charged. Thomsen et al. showed that the
individual basic N-terminal domain of maize HMGB1 binds DNA [30]. Here, we have
shown that the HMO1 C-terminus interacts with both box A and box B and as such, this
interaction could modulate HMO1 affinity for DNA. A change in DNA binding could be
due to a net change in available charges that facilitates DNA interactions, and/or a change
in protein conformation, enabling a better DNA protein interaction. It has previously
been shown that intramolecular interaction of the acidic tail and HMG-box domain(s)
may modulate DNA interactions of HMGB proteins [28, 41, 44, 45]. It would be
interesting to assess if the individual C-terminal tail would fold into an individual domain
and if it would bind DNA. Although deletion of the HMO1 C-terminus does not severely
affect HMO1 affinity for DNA, it completely abolishes its DNA bending properties
(Figure 4.3). NHP6A and HMGB1 basic N-terminal domains have been shown to
enhance the DNA bending properties of these proteins [20, 42], which correlates to these
proteins DNA binding properties. It is apparent that changes in individual HMGB
proteins in DNA binding properties correlate to changes in DNA bending properties.
CKII phosphorylates HMO1
CKII has previously been used in phosphorylation of HMGB serine residues [21,
22, 41]. CKII phosphorylates HMO1 (Figure 4.4, panel A) and HMO1-boxAB, which
lowers the DNA affinity of these proteins, as shown using EMSA (Figure 4.4, panel B).
Protein phosphorylation increases the negative net charge. In this study, we have shown
that CKII phosphorylates HMO1 Ser137 and/or Ser153, both of which are located in box
B. We have previously shown that box A binds DNA but with low affinity [35], hence
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this strengthens the argument that box B confers most of the DNA binding affinity.
Increasing the negative net charge in box B leads to reduction in DNA affinity. This
phenomenon can be explained by the following possible scenarios; 1) electrostatic DNA
repulsion, 2) increasing the negative net charge in box B leads to a stronger interaction
with the C-terminus and as a result, the net positive charge available in box B and/or in
the C-terminal tail that contributes to DNA binding is lowered, or 3) change in protein
conformation and/or stability. The rate at which phosphorylation reduced HMO1 and
HMO1-boxAB affinity for DNA looks similar (Figure 4.3), making the second scenario
less likely since involvement (or lack thereof) of the C-terminal tail does not make a
difference in effect that phosphorylation has in DNA binding of these proteins. It is
interesting also to note that HMO1-boxAB does not bend DNA nor does it supercoil
closed relaxed DNA, before or after phosphorylation (Figure 4.3, data not shown). We
have also shown that protein cleavage with Enterokinase and BNPS-skatole does not
confer a gross change of protein conformation in the presence of DNA or protein
phosphorylation since cleavage patterns remain the same. Therefore, the conformational
changes that HMO1 goes through upon DNA binding and/or after phosphorylation could
not be detected by cleavage with Enterokinase or BNPS-skatole. It would be interesting
to investigate the conformational changes using intrinsic fluorescence and thermal
stability using CD spectroscopy of HMO1 before and after phosphorylation. This would
be critical in trying to understand the role of HMO1 in vivo in its DNA interaction
capacity, since this protein is most likely phosphorylated in vivo. The C-terminus of
HMO1 has been shown to be dispensible for function in vivo [31]. We have shown
HMO1-boxAB to be localized in the cytoplasm, unlike HMO1 which is localized both in
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the nucleus and cytoplasm (unpublished data, [31, 34]). We therefore would like to
propose that the majority functions of HMO1 are located in the cell cytoplasm and not in
the nucleus. Recently, the extranuclear and extracellular functions of HMGB1 have just
started to come into focus. It participates in developmental and differentiation processes,
triggers and modulates many of the inflammatory cascades in the body, and may even be
involved in the metastatic invasion programme of cancer cells (reviewed in [46]). As
such, it is more likely that post-translational modification of HMO1 (phosphorylation)
and HMGB1 plays more crucial role(s) in regulating the function(s) of these proteins in
the cytoplasm than in the nucleus.
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CHAPTER 5
FLUOROQUINOLONE-DEPENDENT DNA SUPERCOILING BY VACCINIA
TOPOISOMERASE I
Introduction
DNA topoisomerases are ubiquitous enzymes that control DNA topology. While
DNA cleavage by all topoisomerases leads to formation of a transient covalent
intermediate in which a tyrosine is linked to a broken DNA strand, type I topoisomerases
relax supercoiled DNA by cleaving only one DNA strand, causing the linking number to
change in steps of one. The type IB enzymes, which form a covalent bond to a 3'phosphate, are found in all eukaryotes, where they relax both positive and negative
supercoils [1-3].
The type IB enzymes of poxviruses are the smallest topoisomerases known.
Vaccinia topoisomerase I is a 314-amino acid protein that binds duplex DNA with
stringent specificity for transesterification at 5'-(C/T)CCTT↓ sites, where the 3'
phosphate of the incised strand becomes linked to Tyr-274 of the enzyme [3-7]. Vaccinia
topoisomerase I consists of two structural modules; the N-terminal module contacts the
cognate DNA site in the major groove, while the C-terminal module comprises an
autonomous catalytic domain [8-11]. The structure of the catalytic domain is similar to
that of human topoisomerase I, except for a displacement of the active site tyrosine [1012].
Vaccinia encapsidates many enzymes that are needed for early viral transcription,
including topoisomerase I. Inactivation of the gene encoding Vaccinia topoisomerase I
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was recently shown to be associated with diminished infectivity in vitro due to reduced
early transcription [13], suggesting that drugs that interfere with Vaccinia topoisomerase
activity have the potential to be developed into effective antiviral agents. Vaccinia
topoisomerase I displays unique pharmacological properties; it is resistant to
camptothecin, otherwise a topoisomerase I poison, but sensitive to inhibitors of bacterial
DNA gyrase such as novobiocin and coumermycin, both coumarin drugs that are used as
antibiotics [14-19].
Fluoroquinolones are topoisomerase II poisons known to target DNA gyrase and
topoisomerase IV in bacterial cells [20-22]. The interaction of norfloxacin with the DNAgyrase complex has been investigated in some detail. While binding of norfloxacin to
gyrase was undetectable, it was shown to bind DNA directly and to exhibit a binding
mode involving preferred recognition of single-stranded DNA. Drug binding was
enhanced by the presence of gyrase, suggesting that DNA-binding revealed a cryptic
norfloxacin binding site on the enzyme [23-24]. The nature of the norfloxacin-DNA
complex has been analyzed by several groups, with somewhat disparate conclusions.
Norfloxacin was reported to require magnesium ions for DNA binding, with Mg2+
proposed to act as a bridge between the negatively charged DNA phosphates and the
carbonyl and carboxyl moieties of norfloxacin [25]. However, more recent reports
showed binding of norfloxacin to DNA in the absence of Mg2+ and suggested a mode of
DNA interaction that ruled out classical DNA intercalation or groove binding, based in
part on the observation that the molecular plane of norfloxacin is nearly perpendicular to
the helix axis [26-27]. These authors also found that DNA unwinding by norfloxacin is
negligible and proposed instead that the compound may induce a bend in the DNA helix.
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The inhibitory effect of fluoroquinolones is based on their ability to stimulate the
forward rate of the topoisomerase II-mediated DNA scission; after binding the cleavable
complex, the fluoroquinolone induces a conformational change in the enzyme that
prevents religation [28-30]. The fluoroquinolone derivative ofloxacin was previously
shown also to exhibit antiviral activity against Vaccinia virus, and the inhibitory activity
shown to correlate with inhibition of topoisomerase I purified from Vaccinia virus cores
[31]. Here we describe a novel interaction of fluoroquinolones with Vaccinia
topoisomerase I in vitro, focusing on enrofloxacin which is structurally closely related to
ciprofloxacin (Figure 5.1). We show here that enrofloxacin inhibits DNA relaxation by
Vaccinia topoisomerase I at lower concentrations than those required for inhibition by
ofloxacin. In the presence of relaxed DNA, enrofloxacin causes Vaccinia topoisomerase I
to supercoil DNA, reversing its action as a DNA relaxing enzyme. Notably, enrofloxacin
does not induce human topoisomerase to supercoil relaxed DNA.
Experimental Procedures
Inhibition of DNA relaxation by fluoroquinolones.
Supercoiled closed circular pUC18 plasmid (0.2 µg) was incubated with 2.5 units
of Vaccinia topoisomerase I (Epicentre; 10 units ~ 6 ng), wheat germ topoisomerase I
(Promega) or human topoisomerase I (TopoGEN) and varying concentrations (2.5 µM to
1250 µM) of enrofloxacin, ofloxacin, norfloxacin, lomefloxacin (Sigma), ciprofloxacin or
moxifloxacin (a generous gift from Bayer Pharmaceuticals) in topoisomerase reaction
buffer (50 mM Tris, pH 7.5, 2.5 mM MgCl2, 100 mM NaCl and 0.1 mM EDTA) for 2
hours at 37°C. Reactions were quenched with 5 µl termination buffer (250 mM Trisborate, 5 mM EDTA (5X TBE), 5% SDS, 15% sucrose, 0.1% bromophenol blue (BPB),
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Figure 5.1 Structure of fluoroquinolones.
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0.1% xylene cyanol, 2 µg/µl proteinase K) and further incubated for 1 h at 37°C, except
where noted. Samples were loaded on 1% 1X TBE agarose gels and electrophoresed at 2
V/cm for 16 h in 1X TBE buffer. Gels were stained with ethidium bromide (EtBr) and
quantified using an Alpha Innotech digital imaging system.
Supercoiling of relaxed DNA by vaccinia topoisomerase in the presence of
fluoroquinolones
Relaxed closed circular pUC18 plasmid was prepared by adding 2.5 units
Vaccinia topoisomerase I to supercoiled pUC18 in topoisomerase reaction buffer for 2 h
after which the DNA was phenol-chloroform extracted and ethanol precipitated.
Supercoiling reactions contained 0.2 µg relaxed closed circular pUC18, 2.5 units of
Vaccinia topoisomerase I and varying concentrations of fluoroquinolone. Reactions were
incubated at 37°C for 2 h, quenched and electrophoresed as described above. To study the
effects of coumermycin on supercoiling of relaxed DNA by Vaccinia topoisomerase I in
the presence of enrofloxacin, varying concentrations of coumermycin (25 µM-500 µM)
were incubated with topoisomerase for 10 minutes before addition of DNA and
enrofloxacin. Reactions were analyzed as described above.
Ligase assay with ethidium bromide and enrofloxacin
Ligase-mediated reactions were initiated by addition of 1 unit of T4 DNA ligase
to a final volume of 20 µl reaction buffer (20 mM Tris-HCl pH 8, 50 mM NaCl, 10 mM
MgCl2, 0.1 mM Na2EDTA, 1 mM DTT, 0.05% BRIJ58) containing 0.2 µg nicked DNA.
(Nicked DNA was prepared by incubation of pUC18 DNA with N.BstNB I (NEB)).
Increasing concentrations of EtBr or enrofloxacin were added, and reactions were
incubated at room temperature for 3 h after which they were quenched by addition of 5 µl
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of termination buffer and further incubated for 1 h at 37°C. Samples were analyzed as
described above.
Two-dimensional analysis of supercoiling
DNA was supercoiled by incubating 0.2 µg relaxed closed circular pUC18, 2.5
units of Vaccinia topoisomerase I and 25 µM enrofloxacin at 37°C for 2 h followed by
addition of termination buffer and a further incubation at 37°C for 1h. To determine the
direction of supercoils introduced by Vaccinia topoisomerase I in the presence of
enrofloxacin, topoisomers were separated by electrophoresis at 2 V for 16 h in 1X TBE
buffer. The gel was soaked in chloroquine (3 µg/ml) for 1 h, turned 90° and run at 4
V/cm for 8 h in 1X TBE buffer, then stained with EtBr and visualized as described above.
Electrophoretic Mobility Shift Assays
An 18/24 duplex DNA containing a single CCCTT motif was used in this
analysis. The top strand (18-mer, either unmodified or 5'-CGTGTCGCCCTT∗ATTCCG3', with the asterisk indicating phosphorothioation) was 5'-end labeled with T4
polynucleotide kinase and [ -32P] ATP and annealed to the bottom strand (24-mer, 5'CACTATCGGAATAAGGGCGACACG-3').

Reactions

were

incubated

at

room

temperature in 10 µl topoisomerase buffer (50 mM Tris-HCl pH 7.5) containing 25 nM
DNA and varying amounts of Vaccinia topoisomerase I. Samples were adjusted to 5%
glycerol

and

resolved

on

prerun

7%

(w/v)

native

polyacrylamide

(39:1

acrylamide:bisacrylamide) gels at 4°C with 0.5X TBE running buffer. Quantification was
performed on a Molecular Dynamics Storm Phosphorimager using software supplied by
the manufacturer.
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Suicide substrate cleavage
The top strand of the non-phosphorothioated 18/24 duplex was 3'-end labeled
with terminal transferase and [ -32P] ATP and annealed to the bottom strand. DNA
cleavage reactions were initiated by addition of 100 units of Vaccinia topoisomerase I to
130 µl of substrate cleavage buffer (10 mM Tris-HCl pH 7.0, 0.1 mM EDTA, 2.5 mM
MgCl2, 2.5 mM CaCl2) containing 500 nM DNA, with or without enrofloxacin. Time
points were taken at 0.5, 1, 5 and 10 minutes. For each time point, 10 µl of the reaction
mixture was quenched by addition of 5 µl termination buffer and further incubated for 1 h
at 37°C. Samples were adjusted to 70% formamide, heated for 4 minutes at 95°C and
resolved on prerun 20% (w/v) polyacrylamide (19:1 acrylamide: bisacrylamide)
denaturing gels with 7M urea in 0.5X TBE. Gels were visualized and quantified on a
Molecular Dynamics Storm Phosphorimager as described above.
Results
Enrofloxacin inhibits DNA relation by topoisomerase I
Enrofloxacin inhibits relaxation of supercoiled plasmid DNA by Vaccinia
topoisomerase I in a concentration-dependent fashion, with complete inhibition at ~1 mM
drug (Figure 5.2). The concentration of enrofloxacin required to inhibit Vaccinia
topoisomerase I is comparable to the effective concentration of the coumarin drugs
novobiocin (~0.5 mM) and coumermycin (~0.2 mM) needed to inhibit DNA relaxation
by Vaccinia topoisomerase I, but lower than the ~2 mM ofloxacin previously seen to
elicit ~30% inhibition of topoisomerase I purified from virus cores [17, 31] Consistent
with this observation, we also find that higher concentrations of ofloxacin are required to
inhibit the enzyme compared to enrofloxacin (data not shown). Enrofloxacin also inhibits
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Figure 5.2 Inhibition of DNA relaxation by enrofloxacin. Reactions contained 0.2 µg
supercoiled pUC18, 2.5 units Vaccinia topoisomerase I, wheat germ topoisomerase I or
human topoisomerase I and increasing concentrations of enrofloxacin (enro): 2.5, 12.5,
62.5, 125, 250 and 1250 µM (lanes 3-9, 10-15, 17-22). Lanes 2, 9 and 16 are relaxation
reactions with no drug added. Lane 1 is the supercoiled DNA. Relaxed (R) and
supercoiled DNA (SC) is identified at the left.
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relaxation of DNA by wheat germ topoisomerase I at equivalent concentrations, but does
not produce any effects on human topoisomerase I within this concentration range
(Figure 5.2).
Vaccinia topoisomerase introduces negative supercoils into relaxed DNA in the presence
of enrofloxacin
Incubation of relaxed closed circular pUC18 DNA with Vaccinia topoisomerase I
and increasing concentration of enrofloxacin resulted in the generation of a distribution of
supercoiled DNA topoisomers (Figure 5.3A); the distribution differs from that seen when
DNA is relaxed by topoisomerase I. The order in which reactants were added did not
affect the efficiency with which Vaccinia topoisomerase I supercoiled relaxed DNA
(Figure 5.3A, lanes 12 and 13). In the presence of enrofloxacin, wheat germ
topoisomerase I also introduced supercoils into relaxed DNA, however, a lower
superhelical density was generated. In contrast, enrofloxacin had no effect on human
topoisomerase I (Figure 5.3B). Note that a distinct population of topoisomers is generated
upon incubation of relaxed DNA with human topoisomerase I, each topoisomer
interdigitating between topoisomers produced by wheat germ or Vaccinia topoisomerase
I (Figure 5.3B, lanes 8 and 9).
To determine the direction of DNA superhelicity, a 2-dimensional agarose gel
electrophoresis was performed. In the presence of chloroquine, negatively supercoiled
DNA topoisomers, separated in the first dimension, lose superhelicity and migrate slower
while positively supercoiled DNA gains superhelicity and migrates faster. Accordingly,
negatively supercoiled topoisomers migrate with a left-handed curvature in the second
dimension (e.g., Figure 5.3D), while positively supercoiled topoisomers generate a right-
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Figure 5.3 Supercoiling of relaxed DNA in the presence of enrofloxacin. (A)
Reactions contained 0.2 µg relaxed pUC18, 2.5 units Vaccinia topoisomerase I,
increasing concentrations of enrofloxacin (enro): 12.5, 25, 50, 75, 125, 175 and 250 µM
(lanes 3-9). In lanes 10 and 11, relaxed DNA was incubated with 30 or 60 µM
enrofloxacin. In lane 12, relaxed DNA was incubated with Vaccinia topoisomerase I for
10 minutes, then 30 µM enrofloxacin was added and the reaction incubated further for 2
h. In lane 13, enrofloxacin was incubated with Vaccinia topoisomerase I for 10 minutes,
after which DNA was added and the reaction incubated further for 2 h. (B) Reaction
mixtures are as above, except with wheat germ topoisomerase I (left panel) and human
topoisomerase I (right panel). Lanes 3-8 and 10-15 contain enrofloxacin (7.5 – 75 µM).
Topoisomers are identified by a bracket, relaxed (R) and supercoiled DNA (SC) is
identified at the left. (C-F) Two-dimensional analysis of supercoiling. The direction of
electrophoresis is indicated. (C) Relaxation of negatively supercoiled DNA by Vaccinia
topoisomerase I yields a distribution of positively supercoiled topoisomers. (D) Negative
supercoils introduced by Vaccinia topoisomerase I in the presence of enrofloxacin. (E)
Positive supercoils introduced by human topoisomerase I in the presence of enrofloxacin.
(F) Positive supercoils introduced by human topoisomerase I in absence of enrofloxacin.
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handed arc after electrophoresis in the second dimension (e.g., Figure 5.3C). While
relaxation by Vaccinia topoisomerase I generates a population of positively supercoiled
topoisomers, negative supercoils are introduced in the presence of enrofloxacin (Figure
5.3C-D). When a 2-dimensional agarose gel electrophoresis was performed on the
population of topoisomers generated by human topoisomerase I in the presence or
absence of enrofloxacin, positive supercoils were detected (Figure 5.3E-F). While
ciprofloxacin and norfloxacin were as efficient as enrofloxacin at inducing the
topoisomerase to produce DNA supercoiling, no effect was seen in the presence of
equivalent concentrations of the structurally related compounds moxifloxacin and
lomefloxacin (Figure 5.4), pointing to specific structural requirements for the observed
interaction. Notably, both compounds found to be ineffective in modulating Vaccinia
topoisomerase I activity contain a C8 substituent (a methoxy group in the case of
moxifloxacin and fluorine for lomefloxacin (Figure 5.1)).
Effects of coumermycin and enrofloxacin on DNA binding by Vaccinia topoisomerase I
Coumermycin inhibits Vaccinia topoisomerase I by blocking its interaction with
DNA [2, 17]. Coumermycin inhibited the enrofloxacin-mediated supercoiling of relaxed
DNA by Vaccinia topoisomerase I at concentrations similar to those required for
inhibition of DNA relaxation (data not shown), suggesting unhindered access of
coumermycin to its binding site in the presence of enrofloxacin and prevention of
enzyme-DNA complex formation.
Enrofloxacin does not modulate the Vaccinia topoisomerase I active site
Vaccinia topoisomerase I displays considerable DNA sequence specificity,
binding and forming a covalent adduct at sites containing the sequence 5'-
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Figure 5.4 Structural specificity of fluoroquinolones. Reaction mixtures are as
described for Figure 3. except that Vaccinia topoisomerase I was incubated with (A)
norfloxacin (0.25, 2.5, 12.5, 62.5, 125, and 250 µM in lanes 3-8), (B) moxifloxacin (2.5,
12.5, 25, 62.5, 125, 250, and 1,250 µM in lanes 3-9) or (C) lomefloxacin (concentrations
as for panel B). Lanes 1 contain supercoiled DNA and lanes 2 relaxed DNA.
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(C/T)CCTT↓ [3, 9]. Suicide substrates have been useful for analysis of DNA cleavage,
containing a single CCCTT↓ cleavage site from which a non-covalently held 6-nt product
is released in preference to religation (Figure 5.5A) [3, 32, 33]. Electrophoretic mobility
shift assays (EMSA) in which Vaccinia topoisomerase I bound either the suicide
substrate or a modified version with a phosphorothioate replacing the scissile
phosphoester bond, thus trapping the covalent intermediate and preventing religation,
showed no interference of enrofloxacin with DNA binding and formation of the covalent
intermediate (data not shown). We also assayed whether enrofloxacin would modify the
rate of Vaccinia topoisomerase I-mediated DNA cleavage under single-turnover
conditions [33]. As determined from initial rates of cleavage product release,
enrofloxacin does not modify the rate of Vaccinia topoisomerase I-mediated DNA
cleavage (Figure 5.5B-C).
Enrofloxacin does not supercoil DNA
Although fluoroquinolones have been reported not to associate with DNA in a
classical intercalative or groove-binding mode that leads to DNA unwinding [26, 27],
several experiments were performed to rule out the possibility that the fluoroquinolones
modulate DNA topology. First, relaxed DNA was incubated with increasing
concentrations of enrofloxacin in the absence of the enzyme. At concentrations up to 60
µM, enrofloxacin had no effect on DNA migration, arguing against an intercalative mode
of interaction with the DNA (Figure 5.3, lanes 10 and 11). Secondly, if enrofloxacin were
merely causing DNA unwinding, then negative supercoils would also be expected to
result from incubation with human topoisomerase I, and that is not observed (Figure 5.3).
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Figure 5.5. Suicide substrate assay. (A) An 18-nt CCCTT-containing oligonucleotide
hybridized to a 24-nt oligonucleotide. (B) Reaction in lane 1 contains substrate DNA with
no enzyme. Lanes 2-6 time-course reactions with 2.5 units of Vaccinia topoisomerase;
reactions were terminated after 0.5, 1, 5 and 10 minutes. Lanes 7-10 are similar to 2-6,
but contain 25 µM enrofloxacin. (C) The fraction of cleaved DNA as a function of time
of incubation.
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Note, however, that the reactions presented in Figures 5.2-5.4 were terminated with
buffer containing SDS, which would be expected to disrupt interactions and release
bound drug. Therefore, if the fluoroquinolone had induced DNA unwinding, and if the
topoisomerase had relaxed the resulting positive DNA supercoils, then removal of bound
drug should cause the DNA to rewind and to form negative supercoils. We tested this
experimentally, noting that Vaccinia topoisomerase I was previously found to relax
positive DNA supercoils preferentially (Figure 5.6) [34]. As expected, incubation of
Vaccinia topoisomerase I with relaxed DNA in the presence of EtBr, which unwinds
DNA ~26° upon binding [35], leads to a distribution of positively supercoiled
topoisomers when reactions are terminated without disruption of the drug-DNA
interactions (Figure 5.6A). Exposure of the reactions to SDS (not shown) or phenolextraction leads to the expected removal of EtBr and formation of negatively supercoiled
topoisomers (Figure 5.6B). By contrast, negatively supercoiled topoisomers are formed
on incubation of Vaccinia topoisomerase I with relaxed DNA in the presence of
enrofloxacin, whether reactions are terminated by treatment with SDS (Figure 5.3),
phenol-extraction (Figure 5.6D) or without disruption of the drug-DNA interaction
(Figure 5.6C), indicating that the observed DNA supercoiling is not due to rewinding of
DNA upon extraction of the drug. Finally, nicked pUC18 was religated with T4 DNA
ligase in the presence of increasing concentrations of EtBr or enrofloxacin (Figure 5.6EF). In the presence of EtBr, religation produced different DNA topoisomers compared to
the control, and as expected, at higher EtBr concentration, the DNA was fully
supercoiled. When religated in the presence of enrofloxacin, the topology of the
covalently closed DNA was not altered.
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Figure 5.6 Enrofloxacin does not modulate DNA topology. (A-D) Two-dimensional
analysis of DNA supercoiling. (A-B) Vaccinia topoisomerase I incubated with relaxed
DNA and EtBr, with reactions terminated without SDS, yielding a distribution of
positively supercoiled DNA topoisomers, as seen also for relaxation of negatively
supercoiled DNA (Figure 3C) (A), or by phenol-extraction, resulting in negatively
supercoiled DNA (B). (C-D) Vaccinia topoisomerase I incubated with relaxed DNA and
enrofloxacin, with reactions terminated without SDS (C) or by phenol-extraction (D), in
both cases yielding negatively supercoiled DNA. The direction of electrophoresis is
indicated. (E) Ligation of nicked DNA in the presence of ethidium bromide (EtBr) or
enrofloxacin. Lane 1 is nicked DNA and lane 2 is religated DNA. Lanes 3-6 are ligation
of nicked DNA with 0.5, 1, 2 and 4 µM EtBr, lanes 7-10 are religation of nicked DNA
with 25, 37.5, 75 and 125 µM enrofloxacin. Topoisomers are identified by a bracket. (F)
Two-dimensional analysis of DNA topoisomers formed by ligation of nicked DNA in the
presence of EtBr.
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Discussion
To relax DNA, Vaccinia topoisomerase I binds non-covalently to duplex DNA
and cleaves one DNA strand with concomitant formation of a transient covalent DNAprotein intermediate, followed by DNA topological changes and religation. The data
presented here show that in the presence of specific fluoroquinolones, Vaccinia
topoisomerase I reverses its role as a DNA relaxing enzyme and introduces DNA
supercoils. As demonstrated for norfloxacin [26, 27], enrofloxacin would also be
expected to bind DNA without inducing significant unwinding (Figure 6). Since the rate
of formation of the covalent topoisomerase-DNA intermediate is equivalent in the
presence or absence of enrofloxacin (Figure 5), we find it less likely that the
topoisomerase binds a preformed DNA-fluoroquinolone complex, and propose instead
that the compound may bind preferentially to DNA that has undergone structural
distortions due to enzyme binding (as suggested for targeting of fluoroquinolones to a
DNA-gyrase complex) [23, 24]. Our data also suggest that Vaccinia topoisomerase I
would bind and cleave its cognate DNA sequence in the presence of the fluoroquinolone,
with steps beyond formation of the transient covalent intermediate modulated by the
drug.
Vaccinia topoisomerase I, which removes an average of five superhelical turns
per cleavage and religation event, was proposed to do so by a free rotation mechanism in
which the non-covalently held DNA swivels in an energetically favorable process to
relieve superhelical tension [32]. In contrast, type II topoisomerases are ATP-dependent
and are believed to operate as molecular clamps, forming an enzyme-operated gate in one
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double-stranded DNA segment and passing the other DNA segment through this gate [36,
39]. DNA gyrase introduces negative supercoils into DNA, a feature that requires the
enzyme to dictate the directionality of strand passage. The mechanism of
fluoroquinolone-mediated supercoiling of DNA by Vaccinia topoisomerase I cannot
involve free rotation because first, supercoiling of DNA is not energetically favorable, yet
this process is ATP-independent, and second, introduced supercoils are negative,
indicating that the enzyme dictates directionality. As the fluoroquinolones have been
shown not to bind DNA in a classical mode that results in DNA underwinding (Figure 6)
[26, 27], and since the observed effect is not a general property of all fluoroquinolones
(Figure 4), we suggest that topological changes in the DNA are driven by protein
interactions.
The N-terminal domain of Vaccinia topoisomerase I interacts with the DNA
major groove while the catalytic C-terminal domain interacts with the minor grove on the
face of the helix that contains the scissile phosphodiester [40]. DNA binding triggers a
conformational change at the interdomain linker, causing Vaccinia topoisomerase I to
bind DNA circumferentially as a C-shaped protein clamp [8-10, 40]. It is possible that
the fluoroquinolone interferes with these conformational changes; the enzyme may adopt
a conformation that does not alter its catalytic activity, yet introduces structural changes
that enables it to wrap the DNA in a toroidal supercoil. The mechanism of free rotation of
DNA to release superhelical tension was proposed in part based on the observation that a
2-6 nt 3'-fragment dissociates in preference to religation and that only 2 bp 3' to the
cleavage site is required for cleavage [4, 41]. However, the enzyme does protect at least
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13 bp downstream of its cleavage site [5]. Whereas these interactions may not be required
for cleavage, our data are consistent with their role in topological changes or religation.
Enrofloxacin does not mediate DNA supercoiling by human topoisomerase I
(Figure 3B). In contrast to Vaccinia topoisomerase I, human topoisomerase I is proposed
to follow a “controlled rotation” mechanism for DNA relaxation, in which ionic
interactions between DNA and protein regulate the DNA winding process [12, 42]. In our
relaxation assays, we obtained the typical Gaussian distribution of positively supercoiled
topoisomers that did not change in the presence of enrofloxacin (Figure 3). The formation
of positively supercoiled topoisomers is consistent with a controlled rotation of DNA in
which contacts to the enzyme, possibly downstream of the cleavage site, serve to orient
the DNA. A difference in mechanism of DNA relaxation between Vaccinia
topoisomerase I and human topoisomerase I may contribute to the differential effects of
enrofloxacin on these two enzymes. Alternatively, the binding site for fluoroquinolones
may be obscured or poorly conserved in the human enzyme. Distinct pharmacological
properties are indeed characteristic of Vaccinia topoisomerase I, which is resistant to
classical topoisomerase I poisons, but sensitive to other gyrase inhibitors such as
coumermycin [2, 17].
The recent observation that inactivation of the gene encoding Vaccinia
topoisomerase I causes decreased infectivity suggests that compounds that target this
enzyme have therapeutic potential [13]. Our data suggest that fluoroquinolones may be
structurally optimized to target poxvirus topoisomerases and to serve as antiviral agents.
This notion is corroborated by a previous report showing that the fluoroquinolone
ofloxacin has selective, antiviral activity against Vaccinia virus in cultured mammalian
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cells [31]. The potential for optimizing fluoroquinolone compounds as antiviral agents
against poxviruses is particularly significant in the face of the threat associated with the
use of smallpox as a biological weapon.
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CHAPTER 6
SUMMARY AND CONCLUSION
Orchestration of DNA topology is critical in diverse cellular processes and its
manipulation has been shown to be one of the central roles played by HMGB proteins
and topoisomerases. For example, it has been shown that the chromosome of Escherichia
coli is maintained in a negatively supercoiled state, and supercoiling levels are affected
by growth phase and a variety of environmental stimuli [1]. A recent study measured the
transcriptional response to a loss of supercoiling caused either by genetic impairment of a
topoisomerase or addition of specific topoisomerase inhibitors during log-phase growth
in E. coli and identified genes whose changes are statistically significant. Transcription of
7% of the genome (306 genes) was rapidly and reproducibly affected by changes in the
level of supercoiling [2]. Thus, the global control of transcription throughout the life
cycle of an organism can be formalized as an interacting network of gene products and
effectors that control RNA polymerase selectivity and effective superhelicity. These
effectors can be proteins, including the HMGB proteins or compounds such as
fluoroquinolones. To better understand this complex puzzle, we characterized HMO1, a
Saccharomyces cerevisiae HMGB protein. We looked at its DNA binding and bending
properties as well its posttranslational modification. We also looked at the effect
fluoroquinolone drugs have in influencing Vaccinia topoisomerase I ability to change
DNA superhelicity.
HMO1 Interaction with DNA
Lu J et al. [3] initially characterized HMO1, indicating that it is required for
normal growth, plasmid maintenance and for regulating the susceptibility of yeast
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chromatin to nuclease. In this work, we show that HMO1 binds linear duplex DNA in a
non-sequence specific manner, and that its divergent box A domain participates in DNA
interactions. While the box A domain contributes modest structure-specific binding, the
box B domain is required for high-affinity binding. HMO1 has only modest preference
for DNA with altered conformations, including DNA with nicks, gaps, overhangs or
loops, as well as for 4-way junction structures and supercoiled DNA. HMO1 binds 4-way
junctions with half-maximal saturation of 19.6±2.2 nM, with only a modest increase in
affinity in the absence of magnesium ions (half-maximal saturation 6.1±1.1 nM). When
HMO1 was phosphorylated with Casein Kinase II (CKII), its DNA binding affinity was
slightly reduced in 4-way junction DNA. Lack of preference for the 4-way junction was
also seen by Yen Y et al. [4] in the non-histone protein 6A (NHP6A). However, binding
to the 4-way junctions DNA is considered to be a common property of the HMGB
proteins (reviewed in [5]).
Ligase-mediated circularization of small DNA fragments has been extensively
utilized as a means of comparing the DNA bending activities of non-sequence specific
DNA bending proteins. Both HMGB1/2 and NHP6A/B catalyze formation of 66 bp
circles, NHP6A/B being more efficient, which has been attributed to the relative stability
of NHP6A/B-DNA complexes compared to HMGB1/2 and HU complexes [6, 7].
However, this could also be due to a difference in the bend angle exerted by these
proteins, with the angle exerted by NHP6A/B facilitating DNA strand recognition by
ligase [6]. HMO1 facilitated formation of circles only with DNA longer than 87 bp DNA,
a lower efficiency that may correspond to either a reduced bend angle or a short residence
time of HMO1 on linear DNA.
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Work by Lu J et al. [3] reported that HMO1 introduces negative supercoils into
relaxed plasmid DNA, and that at high concentrations, HMO1 inhibited the unwinding
reaction. We did not find evidence that HMO1, either phosphorylated or nonphosphorylated, have the capability to introduce supercoils into relaxed plasmid DNA.
This can be explained by the lack of an important intercalating hydrophobic residue
found in many HMGB proteins, but missing in HMO1 box B and SRY (an HMGB
protein that also does not supercoil DNA).
Phosphorylation of HMO1
Casein kinase II (CKII) has previously been used in phosphorylation of HMGB
serine residues [8, 9, 10]. We have shown in our study that CKII phosphorylates HMO1
and HMO1-boxAB but not HMO1-boxA. Protein phosphorylation increases the negative
net charge, altering the conformation, stability and DNA binding properties of proteins.
Phosphorylated HMO1 and HMO1-boxAB had reduced affinity for DNA.
HMO1 Thermal Stability
Thermal stability of HMO1 and HMO1-boxAB was measured by CD
spectroscopy. We have shown that HMO1 and HMO1-boxAB goes though a biphasic
thermal denaturation process, but that HMO1-boxA has a single transition. Our data
strongly suggests that the C-terminal tail interacts with both box A and box B, lowering
the melting temperature of these domains. This phenomenon, that the basic extensions of
an HMGB protein cause a reduction of melting temperature, has been reported elsewhere
[11]. We have also concluded from our data that the first transition seen in both HMO1
and HMO1-boxAB is melting of box A and the second transition is melting of box B.
However, purification and characterization of box B would address this interpretation.

125

Phosphorylation of HMGB proteins has shown that phosphates contribute to stability of
the protein [12]. It would also be interesting to look at the effect of phosphorylation on
stability of HMO1 and HMO1-boxAB.
HMO1 Cellular Localization
The C-terminus of HMO1 is dispensible for function in vivo [3]. We have
localized HMO1 without the C-terminus (HMO1-boxAB) to the cytoplasm. This is a
clear indication that the essential and unique functions of HMO1 are located in the
cytoplasm and not in the nucleus, and especially since HMO1 has weak DNA binding
and bending properties compared to other HMGB proteins. This data is supported by the
fact that HMO1 genetically and physically interacts with cytoplasmically expressed
FKBP12 Prolyl Isomerase, a product of the FPR1 gene, which when mutated has been
shown to be synthetic lethal with ∆hmo1[13].
HMGB1 is a nuclear, extranuclear and extracellular protein that participates in
many signaling processes in the cell. (reviewed in [14]). Interesting, our data implicate
HMO1 to function in the extranuclear maybe at similar capacity as HMGB1. Notably,
signaling by TOR (Target of Rapamycin) kinases is central to environmental stress
responses in yeast. Suppression of TOR signaling, for example through inhibition of TOR
kinases by interaction with FKBP12-rapamycin, leads to cell cycle arrest (reviewed in
[15]). The reported interaction between HMO1 and FKBP12 suggest a possible role for
HMO1 in such signaling pathways. Studies to characterize the extranuclear function of
HMO1 will further expand signalling roles of HMGB proteins beyond HMGB1, which
thus far is the only HMGB protein that has been shown to have signaling capabilities,
expanding the importance of HMGB proteins across organisms.
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Vaccinia Topoisomerase I Supercoils DNA in the Presence of Fluoroquinolones
Vaccinia topoisomerase I is a site-specific DNA strand transferase that acts
through a DNA-(3'-phosphotyrosyl)-enzyme intermediate, resulting in relaxation of
supercoiled DNA. Although Vaccinia topoisomerase I is not an essential enzyme, its role
in early transcription makes it a potential antiviral target. We have shown that Vaccinia
topoisomerase I interact with enrofloxacin and a few other fluoroquinolone compounds,
and that these compounds inhibit DNA relaxation. When Vaccinia topoisomerase I is
presented with relaxed DNA in the presence of enrofloxacin, it executes the reverse
reaction, supercoiling the DNA. However, the function does not interfere with the
catalytic cleavage site, nor does it interfere with enzyme’s ability to bind DNA. The
mechanism with which Vaccinia topoisomerase I supercoils relaxed DNA, an
energetically unfavorable, yet ATP-independent process, must entail protein-DNA
contacts downstream of the cleavage site, as opposed to the free rotation mechanism
proposed for DNA relaxation. These characteristics of Enrofloxacin-Vaccinia
topoisomerase I interactions presents a tool to study conformational dynamics of
topoisomerase I.
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